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A B S T R A C T
Background
Hypertensive disorders in pregnancy are significant contributors to maternal and perinatal morbidity and mortality. These disorders in-
clude well-controlled chronic hypertension, gestational hypertension (pregnancy-induced hypertension) and mild pre-eclampsia. The de-
finitive treatment for these disorders is planned early delivery and the alternative is to manage the pregnancy expectantly if severe un-
controlled hypertension is not present, with close maternal and fetal monitoring. There are benefits and risks associated with both, so it
is important to establish the safest option.
Objectives
To assess the benefits and risks of a policy of planned early delivery versus a policy of expectant management in pregnant women with
hypertensive disorders, at or near term (from 34 weeks onwards).
Search methods
We searched Cochrane Pregnancy and Childbirth Trials Register (12 January 2016) and reference lists of retrieved studies.
Selection criteria
Randomised trials of a policy of planned early delivery (by induction of labour or by caesarean section) compared with a policy of delayed
delivery ("expectant management") for women with hypertensive disorders from 34 weeks' gestation. Cluster-randomised trials would
have been eligible for inclusion in this review, but we found none.
Studies using a quasi-randomised design are not eligible for inclusion in this review. Similarly, studies using a cross-over design are not
eligible for inclusion, because they are not a suitable study design for investigating hypertensive disorders in pregnancy.
Data collection and analysis
Two review authors independently assessed eligibility and risks of bias. Two review authors independently extracted data. Data were
checked for accuracy.
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Main results
We included five studies (involving 1819 women) in this review.
There was a lower risk of composite maternal mortality and severe morbidity for women randomised to receive planned early delivery
(risk ratio (RR) 0.69, 95% confidence interval (CI) 0.57 to 0.83, two studies, 1459 women (evidence graded high)). There were no clear differ-
ences between subgroups based on our subgroup analysis by gestational age, gestational week or condition. Planned early delivery was
associated with lower risk of HELLP syndrome (RR 0.40, 95% CI 0.17 to 0.93, 1628 women; three studies) and severe renal impairment
(RR 0.36, 95% CI 0.14 to 0.92, 100 women, one study).
There was not enough information to draw any conclusions about the effects on composite infant mortality and severe morbidity. We
observed a high level of heterogeneity between the two studies in this analysis (two studies, 1459 infants, I2 = 87%, Tau2 = 0.98), so we did
not pool data in meta-analysis. There were no clear differences between subgroups based on our subgroup analysis by gestational age,
gestational week or condition. Planned early delivery was associated with higher levels of respiratory distress syndrome (RR 2.24, 95%
CI 1.20 to 4.18, three studies, 1511 infants), and NICU admission (RR 1.65, 95% CI 1.13 to 2.40, four studies, 1585 infants).
There was no clear difference between groups for caesarean section (RR 0.91, 95% CI 0.78 to 1.07, 1728 women, four studies, evidence
graded moderate), or in the duration of hospital stay for the mother after delivery of the baby (mean difference (MD) -0.16 days, 95%
CI -0.46 to 0.15, two studies, 925 women, evidence graded moderate) or for the baby (MD -0.20 days, 95% CI -0.57 to 0.17, one study, 756
infants, evidence graded moderate).
Two fairly large, well-designed trials with overall low risk of bias contributed the majority of the evidence. Other studies were at low or
unclear risk of bias. No studies attempted to blind participants or clinicians to group allocation, potentially introducing bias as women
and staL would have been aware of the intervention and this may have affected aspects of care and decision-making.
The level of evidence was graded high (composite maternal mortality and morbidity), moderate (caesarean section, duration of hospital
stay after delivery for mother, and duration of hospital stay after delivery for baby) or low (composite infant mortality and morbidity).
Where the evidence was downgraded, it was mostly because the confidence intervals were wide, crossing both the line of no effect and
appreciable benefit or harm.
Authors' conclusions
For women suffering from hypertensive disorders of pregnancy after 34 weeks, planned early delivery is associated with less composite
maternal morbidity and mortality. There is no clear difference in the composite outcome of infant mortality and severe morbidity; how-
ever, this is based on limited data (from two trials) assessing all hypertensive disorders as one group.
Further studies are needed to look at the different types of hypertensive diseases and the optimal timing of delivery for these conditions.
These studies should also include infant and maternal morbidity and mortality outcomes, caesarean section, duration of hospital stay
after delivery for mother and duration of hospital stay after delivery for baby.
An individual patient meta-analysis on the data currently available would provide further information on the outcomes of the different
types of hypertensive disease encountered in pregnancy.
P L A I N   L A N G U A G E   S U M M A R Y
Is it safer to deliver a baby immediately or wait if the mother has high blood pressure after 34 weeks of pregnancy that is not
persistently severe?
What is the issue?
Women who have high blood pressure (hypertension) during pregnancy or who develop pre-eclampsia (high blood pressure with protein
in the urine or other organ systems involvement, or both) can develop serious complications. Potential complications for the mother
are worsening of pre-eclampsia, development of seizures and eclampsia, HELLP syndrome (haemolysis, elevated liver enzymes and low
platelet count), detachment of the placenta, liver failure, renal failure, and difficulty breathing because of fluid in the lungs.
Delivering the baby usually stops the mother’s high blood pressure from getting worse, but a baby who is born prematurely may have
other health problems, such as difficulty breathing, because the lungs are still immature. Induction of labour can lead to overstimulation
of contractions and fetal distress. The alternative is waiting to deliver the baby while closely monitoring both the mother and her baby.
Why is this important?
As there are both benefits and risks to planned early delivery compared with waiting when the mother has high blood pressure toward
the end of pregnancy, we wanted to know which is the safest option. We looked for clinical trials that compared planned early delivery, by
induction of labour or by caesarean section, with a policy of delayed delivery of the baby.
What evidence did we find?
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We searched for evidence on 12 January 2016 and found five randomised studies, involving 1819 women. Two of the studies were large,
high-quality studies, in women with gestational hypertension, mild pre-eclampsia or deteriorating existing hypertension at 34 to 37 weeks
(704 women) or with gestational hypertension or mild pre-eclampsia at 36 to 41 weeks (756 women). Fewer women who received planned
early delivery experienced severe adverse outcomes (1459 women, high-quality evidence). There was not enough information to draw any
conclusions about the effects on the number of babies born with poor health, with a high level of variability between the two studies
(1459 infants, low-quality evidence). There was no clear difference between planned early delivery and delayed delivery for the number of
caesarean sections (four studies, 1728 women, moderate-quality evidence), or the duration of the mother’s hospital stay after the birth of
the baby (two studies, 925 women, moderate-quality evidence) (or for the baby (one study, 756 infants, moderate-quality evidence)). More
babies who were delivered early had breathing problems (respiratory distress syndrome, three studies, 1511 infants), or were admitted to
the neonatal unit (four studies, 1585 infants). Fewer women who delivered early developed HELLP syndrome (three studies, 1628 women)
or severe kidney problems (one study, 100 women).
Two studies compared women who had labour induced at 34 to 36 weeks and at 34 to 37 weeks with a comparison group who were
monitored until 37 weeks, when induction was begun if labour had not started spontaneously. Three studies compared induction of labour
at term or closer to term, at 37 completed weeks and at 36 to 41 weeks, with women who were monitored until 41 weeks when induction
was begun if labour had not started spontaneously. Other inclusion and exclusion criteria also differed between the five studies.
No studies attempted to blind the women or their clinicians to which group they were in. Women and staL were aware of the intervention
and this may have affected aspects of care and decision-making. Most of the evidence was of moderate quality, so we can be moderately
certain about the findings.
What does this mean?
Overall, if a woman’s baby was delivered immediately after 34 weeks, there was less risk of a complication for the mother and no clear
difference in the overall rate of complications for the baby, but information was limited.
These findings are applicable to general obstetric practice when high blood pressure disorders during pregnancy are considered together.
Further studies are needed to look at the different types of hypertensive disorders individually.
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Summary of findings for the main comparison.   Planned early delivery versus expectant management for hypertensive disorders from 34 weeks'
gestation to term
Planned early delivery versus expectant management for hypertensive disorders from 34 weeks' gestation to term
Patient or population: pregnant women with hypertensive disorders from 34 weeks' gestation to term
Setting: 2 studies in the Netherlands, 1 in India, and 1 in the USA
Intervention: planned early delivery
Comparison: expectant management
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
placebo
Risk with
GRADE
Relative effect
(95% CI)
№ of participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study population
242 per 1000 167 per 1000
(138 to 201)
Moderate
Composite maternal mortality and
morbidity
235 per 1000 162 per 1000
(134 to 195)
RR 0.69
(0.57 to 0.83)
1459
(2 RCTs)
⊕⊕⊕⊕
HIGH
 
 Composite infant mortality and mor-
bidity
   
not pooled 1459
(2 RCTs)
  This out-
come was not
pooled, due
to substantial
statistical het-
erogeneity (I2
= 87%, Tau2 =
0.98)
Study population
267 per 1000 243 per 1000
(208 to 285)
Caesarean section
Moderate
RR 0.91
(0.78 to 1.07)
1728
(4 RCTs)
⊕⊕⊕⊝
MODERATE 1
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302 per 1000 275 per 1000
(236 to 324)
Duration of hospital stay after delivery
for mother (days)
The mean du-
ration of hos-
pital stay after
delivery for
mother (days)
was 0
The mean du-
ration of hos-
pital stay after
delivery for
mother (days)
in the inter-
vention group
was 0.16 few-
er (0.46 fewer
to 0.15 more)
- 925
(2 RCTs)
⊕⊕⊕⊝
MODERATE 1
 
Duration of hospital stay after delivery
for baby (days)
The mean du-
ration of hos-
pital stay after
delivery for
baby (days)
was 0
The mean du-
ration of hos-
pital stay after
delivery for
baby (days)
in the inter-
vention group
was 0.2 days
fewer (0.57
fewer to 0.17
more)
- 756
(1 RCT)
⊕⊕⊕⊝
MODERATE 1
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1Wide confidence interval crossing the line of no effect.
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B A C K G R O U N D
Description of the condition
Hypertensive disorders in pregnancy are significant contributors to
maternal and perinatal morbidity and mortality in low-, middle-
and high-income countries (Khan 2006). They occur in up to 10% of
all pregnancies (Dolea 2003; Saftlas 1990; Steegers 2010) and in up
to 11% of first pregnancies (Villar 2003). There is wide variation in
the incidence between different countries, and regional differences
may exist (Abalos 2013). This may be explained by differences in
maternal age distribution, the proportion of primiparous women
among the populations (Hutcheon 2011), and dietary differences
such as low-calcium intake (Belizan 1980) and genetic characteris-
tics.
There are a number of classification systems for the hypertensive
disorders of pregnancy. The most recent classification system that
has been published is from the International Society for the Study
of Hypertensive Disorders in Pregnancy (ISSHP) (Magee 2014). Oth-
er commonly-used classification systems are the National Institute
for Health and Clinical Excellence (NICE) classification system (NICE
2010), which is currently under review, and the American College of
Obstetricians and Gyneologists classification of Hypertensive dis-
orders in pregnancy (ACOG Hypertension in Pregnancy 2013).
The ISSHP classification
Hypertension in pregnancy: office or in-hospital systolic blood
pressure (BP) greater than or equal to 140 mmHg and/or a diastolic
blood pressure greater than or equal to 90 mmHg on the average of
at least two measurements, taken at least 15 minutes apart, using
the same arm.
Severe hypertension: systolic blood pressure greater than or
equal to 160 mmHg or a diastolic blood pressure greater than or
equal to 110 mmHg on the average of at least two measurements,
taken at least 15 minutes apart, using the same arm.
Pre-existing (chronic) hypertension: hypertension that predates
the pregnancy or appears before 20 weeks' gestation.
Gestational hypertension: hypertension that appears at or after
20 weeks of gestation.
Pre-eclampsia: gestational hypertension and new proteinuria or
one or more adverse conditions or one or more serious complica-
tions (see Table 3 for definitions of adverse conditions and serious
complications).
In this classification an adverse condition consists of maternal
symptoms, signs, abnormal laboratory results and abnormal fetal
monitoring that may herald the development of severe maternal
or fetal complications and significant proteinuria is a value greater
than or equal to 0.3 g/d in a complete 24-hour urine collection or
a spot (random) urine sample with greater than or equal to 30 mg/
mmol urinary creatinine.
Severe pre-eclampsia: pre-eclampsia associated with a severe
complication that warrants delivery regardless of gestational age.
NICE classification
Pre-existing/chronic hypertension: hypertension defined as a
systolic blood pressure above 140 mmHg or diastolic blood pres-
sure above 90 mmHg prior to pregnancy or hypertension present-
ing in the first 20 weeks of pregnancy, (on at least two occasions)
or hypertension persisting until at least 12 weeks postpartum or if
the woman is already taking antihypertensive medication when re-
ferred to maternity services. It can be primary (essential hyperten-
sion) or secondary (to various medical conditions) in aetiology.
Gestational hypertension: elevated blood pressure (systolic
blood pressure above 140 mmHg and diastolic blood pressure
above 90 mmHg measured on two occasions at least four hours
apart) in previously normotensive pregnant women presenting af-
ter 20 weeks of pregnancy without proteinuria.
Severe gestational hypertension: elevated systolic blood pres-
sure of more than 160 mmHg and/or diastolic blood pressure of
more than 110 mmHg at least four hours apart.
The diagnosis of gestational hypertension is temporary and be-
comes pre-eclampsia if proteinuria develops, or chronic hyperten-
sion if blood pressure is still elevated at 12 weeks postpartum, or
transient hypertension of pregnancy if the blood pressure is nor-
mal at 12 weeks postpartum (Magloire 2012). About 15% to 25% of
women with gestational hypertension will develop pre-eclampsia
(Davis 2007). This may increase up to 46% the earlier the diagnosis
of gestational hypertension is made (Barton 2001).
Pre-eclampsia: hypertension (systolic blood pressure above 140
mmHg and diastolic blood pressure above 90 mmHg) measured
on two occasions at least four hours apart presenting after 20
weeks with significant proteinuria (urinary protein: creatinine ratio
greater than 30 mg/mmol or more than 0.3 g in a validated 24-hour
urine specimen).
Severe pre-eclampsia: pre-eclampsia with severe hypertension
(systolic blood pressure above 160 mmHg and/or diastolic blood
pressure above 110 mmHg) or other signs/symptoms such as symp-
toms of central nervous system dysfunction, liver capsule disten-
sion, liver impairment, thrombocytopenia (decrease in the num-
ber of platelets), severe proteinuria of more than 3 g in 24 hours or
3+ on dipstick, renal impairment, oliguria (less than 500 mL in 24
hours), pulmonary oedema, intrauterine growth restriction or re-
duced liquor volume (Duley 2009).
Pre-eclampsia superimposed on pre-existing hypertension:
new onset of proteinuria after 20 weeks of pregnancy in a woman
with pre-existing hypertension. In cases where proteinuria is
present in early pregnancy, pre-eclampsia is defined as worsening
of hypertension or development of symptoms/signs of severe pre-
eclampsia (August 2012).
Complications of hypertensive disorders during pregnancy are
associated with worsening of pre-eclampsia, development of
eclampsia, HELLP syndrome (haemolysis, elevated liver enzymes
and low platelet count), placental abruption, liver failure, renal fail-
ure, pulmonary oedema, and maternal death (Sibai 2005).
ACOG Hypertension in Pregnancy Classification
Pre-eclampsia: Blood pressure greater than or equal to 140 mmHG
systolic or greater than or equal to 90 mmHg diastolic on two oc-
casions at least 4 hours apart after 20 weeks of gestation in a
woman with a previously normal blood pressure OR a blood pres-
sure greater than or equal to 160 mmHg systolic or greater than
or equal to 110 mm Hg diastolic, confirmed within a short interval
Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
6
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
to facilitate timely antihypertensive therapy with proteinuria, de-
fined as greater than or equal to 300 mg per 24-hour urine collec-
tion or a protein/creatinine ratio greater than or equal to 0.3 mg/
dL or a dipstick reading of 1+ if other quantitative methods are not
available or in the absence of proteinuria, new onset hypertension
with thrombocytopaenia, renal insufficiency, impaired liver func-
tion, pulmonary oedema or cerebral or visual symptoms.
Chronic hypertension: High blood pressure known to predate con-
ception or detected before 20 weeks of gestation.
Chronic hypertension with superimposed pre-eclampsia: In-
clude the following scenarios:
1. Women with hypertension only in early gestation who develop
proteinuria after 20 weeks of gestation.
2. Women with hypertension and proteinuria before 20 weeks who
develop a sudden exacerbation of hypertension, suddenly manifest
other signs and symptoms such as an increase in liver enzymes,
present with thrombocytopaenia, manifest with symptoms of right
upper quadrant pain and severe headaches, develop pulmonary
oedema or congestion, develop renal insufficiency or have sudden
substantial sustained increases in protein excretion.
Gestational hypertension: New onset hypertension after 20 weeks
gestation in the absence of accompanying proteinuria.
Description of the intervention
The definitive treatment of hypertensive disorders related to preg-
nancy is planned early delivery. The alternative is to manage the
pregnancy expectantly with close maternal and fetal monitoring.
The generic Cochrane protocols on interventions for preventing
(Meher 2005) and treating (Duley 2009) pre-eclampsia and its con-
sequences cite various Cochrane Reviews covering this subject. The
World Health Organization (WHO) guidelines on prevention and
treatment of pre-eclampsia and eclampsia provide a summary of
available evidence on various interventions (WHO 2011). There are
currently no data from randomised controlled trials on interven-
tions to monitor women with hypertensive disorders of pregnancy.
The general approach on management involves frequent blood
pressure measurement, frequent assessment of maternal symp-
toms (headache, blurred vision, epigastric or abdominal pain, vagi-
nal bleeding, decrease in fetal movements), urine analysis for pro-
tein with urine dipstick or ratio of protein to creatinine, and blood
tests to assess renal and liver function, platelets and haemoglo-
bin depending on the severity of the condition. For pre-eclampsia
bloods are taken at least twice weekly if the maternal condition is
stable or more frequently if there is any suspicion of clinical dete-
rioration. For chronic hypertension and gestational hypertension,
bloods are not routinely taken. Fetal monitoring is done by assess-
ing fetal movements felt by the mother, fetal heart rate monitoring
and fetal ultrasound (amniotic fluid measurement, fetal growth,
and Doppler velocimetry in the umbilical artery, middle cerebral
artery and ductus venosus) (Norwitz 2013).
Indications for delivery of women being managed expectantly
would include deterioration of blood pressure control despite an-
tihypertensive treatment, new onset maternal symptoms which
include severe headache, blurred vision, epigastric or abdominal
pain, vaginal bleeding and a decrease in fetal movements, deterio-
ration in blood tests and a change in fetal condition.
Bed rest (Meher 2005), dietary salt restriction (Meher 2005), vitamin
D supplementation (De Regil 2011), vitamin C and E supplementa-
tion, and thiazide diuretics are not recommended for prevention
of pre-eclampsia (WHO 2011). Calcium supplementation is recom-
mended in areas with low dietary calcium intake (Hofmeyr 2014).
Low-dose aspirin, started before 16 weeks, is recommended for the
prevention of pre-eclampsia in women who have risk factors for
pre-eclampsia (Bujold 2014). Based on expert opinion, severe hy-
pertension during pregnancy should be treated with antihyperten-
sive drugs and the choice of the drug is leF to the clinician manag-
ing the woman (WHO 2011).
The timing of delivery is based on the severity of the maternal
condition, gestational age and fetal condition. The indications for
planned early delivery (or contraindications for expectant man-
agement) include: instability of maternal condition; persistent se-
vere hypertension unresponsive to medical therapy; persistent
progressive or severe headache; visual disturbances; eclampsia;
cerebrovascular events; posterior reversible encephalopathy syn-
drome (PRES); epigastric or abdominal pain; leF ventricular failure;
pulmonary oedema; severe renal impairment with a creatinine lev-
el greater than or equal to 125 μmol/l; the need for dialysis or re-
nal failure; abruptio placenta; non-reassuring fetal testing (non-re-
assuring fetal heart rate tracing, estimated fetal weight less than
fiFh centile, oligohydramnios, persistent absent or reversed end-
diastolic flow in umbilical artery Doppler); fetal demise; laboratory
abnormalities (liver transaminases greater than or equal to 500 IU/
L, progressive decrease in platelet count to less than 100 × 109/L,
coagulopathy with an INR greater than 2 in the absence of an alter-
native cause); preterm labour; preterm premature rupture of mem-
branes; HELLP syndrome (Norwitz 2013).
The potential implications for the mother and fetus of expectant
management are weighed against the possible complications of an
earlier delivery.
Traditionally, the management of hypertensive disorders in preg-
nancy at or near term (from 34 weeks onwards) has been a planned
early delivery by induction of labour or caesarean section. Cur-
rently, there is a tendency in high-income countries to continue
with expectant management in the absence of severe pre-eclamp-
sia past 34 0/7 gestational weeks. Canadian guidelines recommend
planned early delivery after 37 0/7 weeks in case of pre-eclampsia
and expectant management before 34 0/7 weeks. In case of non-
severe pre-eclampsia there is insufficient evidence to recommend
planned early delivery between 34 0/7 to 36 6/7 weeks (Magee
2008).
Based on a recent literature review by Spong 2011, planned early
delivery is recommended:
• at 38 to 39 weeks for women with chronic hypertension on no
medications;• at 37 to 39 weeks for women with chronic hypertension con-
trolled on medications;• at 36 to 37 weeks for women with chronic hypertension difficult
to control;• at 37 to 38 weeks for women with gestational hypertension;• at diagnosis for women with severe pre-eclampsia (at or after 34
weeks);• at 37 weeks for women with mild pre-eclampsia.
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How the intervention might work
Planned early delivery by induction of labour or indicated caesare-
an section is thought to have the following benefits:
• prevention of severe maternal complications in women with hy-
pertensive disorders in pregnancy;• prevention of poor fetal outcomes and stillbirth.
Potential risks of planned early delivery by induction of labour are:
• increased risk of complications associated with induction of
labour such as uterine hyperstimulation and fetal distress;
Potential risks of planned early delivery by induction of labour or
caesarean section are:
• concerns related to prematurity. Although the adverse out-
comes due to prematurity are uncommon after 34 0/7 weeks
of gestation, several recent reports have highlighted increased
rates of neonatal morbidity related to respiratory distress syn-
drome, need for ventilation and neonatal intensive care admis-
sion when elective caesarean sections were performed before
39 0/7 weeks of gestation (Maslow 2000; Tita 2009; Wilmink
2010). Infants born between 37 0/7 and 38 6/7 weeks have
greater neonatal morbidity during the first year of life in com-
parison with infants born between 39 0/7 and 41 0/7 weeks (Di-
etz 2012). Near-term infants have significantly more health prob-
lems and increased healthcare costs compared with full-term in-
fants in the first year of life and later on (Boyle 2012; Wang 2004).
The intervention being investigated is timing of delivery. Prolong-
ing gestation may be better for the fetus but it may increase the
risks of complications for the mother.
Why it is important to do this review
There are benefits and risks associated with both policies (planned
early delivery and expectant management) in women with hyper-
tensive disorders of pregnancy. It is therefore important to estab-
lish the safest option associated with more favourable maternal
and neonatal outcomes in such cases.
Management of severe pre-eclampsia before term is dealt with in
another Cochrane Review comparing interventionist and expec-
tant care (Churchill 2013).
O B J E C T I V E S
To assess the benefits and risks of a policy of planned early delivery
versus a policy of expectant management in pregnant women with
hypertensive disorders, at or near term (from 34 weeks onwards).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included adequately randomised controlled trials comparing
planned early delivery (induction of labour or caesarean section)
with expectant management of women with hypertensive disor-
ders from 34 weeks' gestation to term. We would have included
cluster-randomised trials but we found none. Studies using a qua-
si-randomised design are not eligible for inclusion in this review.
Similarly, studies using a cross-over design are not eligible for in-
clusion, because they are not a suitable study design for investigat-
ing hypertensive disorders in pregnancy.
Types of participants
Women with hypertensive disorders at 34 weeks 0 days of gestation
or longer.
Types of interventions
Comparison of a policy of planned early delivery (by induction of
labour or by caesarean section) with a policy of delayed delivery
(expectant management).
Types of outcome measures
Primary outcomes
1. Composite maternal outcome, including maternal mortality
(death during pregnancy or up to 42 days after delivery) and se-
vere morbidity (eclampsia; cerebral vascular event; pulmonary
oedema as defined by trial authors; severe renal impairment,
defined as a creatinine level greater than 125 μmol/l or a need
for dialysis or urine output less than 0.5 mL/kg/hour for four
hours unresponsive to hydration with two intravenous bolus-
es, or as defined by trial authors; liver haematoma or rup-
ture; liver failure, defined as the rapid impairment of synthet-
ic function and development of encephalopathy or as defined
by trial authors; haemolysis elevated liver enzymes and low
platelets (HELLP) syndrome; disseminated intravascular coagu-
lation (DIC); thromboembolic disease; and abruptio placentae,
defined as a retroplacental clot of more than 15% of the mater-
nal surface or as defined by trial authors).
2. Composite perinatal outcome, including fetal or neonatal death
(within six weeks after the expected due date or as defined by tri-
al authors); grade III or IV intraventricular or intracerebral haem-
orrhage; necrotising enterocolitis (NEC); acute respiratory dis-
tress syndrome (ARDS) or grade III/IV hyaline membrane dis-
ease; small-for-gestational age (growth below the 10th centile
or as defined by trial authors); and neonatal seizures.
Secondary outcomes
Maternal
1. Maternal mortality as described above
2. Eclampsia
3. Cerebrovascular event
4. Pulmonary oedema as defined above
5. Severe renal impairment as defined above
6. Liver haematoma or rupture*
7. Liver failure as defined above
8. HELLP syndrome
9. DIC
10.Thromboembolic disease
11.Abruptio placentae
12.Antepartum haemorrhage
13.Postpartum haemorrhage (blood loss of more than 500 mL or
more within 24 hours of delivery)
14.Severe hypertension (systolic blood pressure greater than or
equal to 160 mmHg or a diastolic blood pressure greater than
110 mmHg)
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15.Caesarean section
16.Assisted delivery (ventouse/forceps)
17.Maternal morbidity of caesarean section (wound infection,
wound dehiscence, endometritis, postpartum haemorrhage
(blood loss greater than 500 mL), urinary or bowel problems, ve-
nous thrombosis)
18.Maternal morbidity related to induction of labour (uterine hy-
perstimulation, uterine rupture, hyponatraemia, hypotension,
chorioamnionitis, cord prolapse, failed induction)
19.Admission to a high care or intensive care unit*
20.Women's experiences and views on the interventions: pregnan-
cy and childbirth experience, physical and psychological trau-
ma, mother-infant interaction and attachment
Fetal and neonatal
1. Fetal death
2. Neonatal death as defined above
3. Grade III or IV intraventricular or intracerebral haemorrhage
4. NEC
5. ARDS or grade III/IV hyaline membrane disease
6. Small-for-gestational age as defined by trial authors
7. Neonatal seizures
8. Apgar score less than seven at five minutes
9. Cord blood pH less than 7.1 or as defined by trial authors
10.Surfactant use*
11.Neonatal intensive care unit or high care unit admission*
12.Intubation and mechanical ventilation or continuous positive
airway pressure support
13.Early neonatal sepsis*
Use of health-service resources
1. Duration of hospital stay after delivery for mother
2. Duration of hospital stay after delivery for baby
Economic outcomes
1. Costs to health service resources: short-term and long-term for
both mother and baby
2. Costs to the woman, her family, and society
* denotes that outcome was not specified in this review's protocol
and was added at the review stage.
Search methods for identification of studies
The following Methods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (1 January 2016).
The Register is a database containing over 22,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy and Childbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MEDLINE,
Embase and CINAHL; the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service, please follow this link to the editorial informa-
tion about the Cochrane Pregnancy and Childbirth in the Cochrane
Library and select the ‘Specialized Register ’ section from the op-
tions on the leF side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials iden-
tified from:
1. monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major con-
ferences;
6. weekly current awareness alerts for a further 44 journals plus
monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is then
added to the Register. The Information Specialist searches the Reg-
ister for each review using this topic number rather than keywords.
This results in a more specific search set which has been fully ac-
counted for in the relevant review sections (Included studies; Ex-
cluded studies; Ongoing studies).
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
The following Methods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors independently assessed all the potential stud-
ies we identified as a result of the search strategy. We resolved any
disagreement through discussion and did not need to consult a
third person.
We included one study published in abstract only, as it was as-
sessed as eligible (Majeed 2014).
Data extraction and management
We designed a form to extract data. For eligible studies, two review
authors extracted the data using the agreed form. We resolved dis-
crepancies through discussion and did not need to consult a third
person. We entered data into Review Manager 5 software (RevMan
2014) and checked them for accuracy.
When information regarding any of the above was unclear, we at-
tempted to contact authors of the original reports to provide fur-
ther details.
Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
9
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Assessment of risk of bias in included studies
Two review authors independently assessed risks of bias for each
study using the criteria outlined in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). We resolved any
disagreement by discussion and did not need to involve a third as-
sessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random number
table; computer random number generator);• high risk of bias (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation; con-
secutively-numbered sealed opaque envelopes);• high risk of bias (open random allocation; unsealed or non-
opaque envelopes; alternation; date of birth);• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies are
at low risk of bias if they were blinded, or we judged that the lack of
blinding would be unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
  Where sufficient information was reported, or could be supplied by
the trial authors, we re-included missing data in the analyses which
we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome
data balanced across groups and are unlikely to influence the
outcome; missing data have been imputed using appropriate
methods);• high risk of bias (e.g. numbers or reasons for missing data im-
balanced across groups; ‘as treated’ analysis done with substan-
tial departure of intervention received from that assigned at ran-
domisation);• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the pos-
sibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s prespec-
ified outcomes and all expected outcomes of interest to the re-
view have been reported);• high risk of bias (where not all the study’s prespecified outcomes
have been reported; one or more reported primary outcomes
were not prespecified; outcomes of interest are reported incom-
pletely and so cannot be used; study fails to include results of
a key outcome that would have been expected to have been re-
ported);• unclear risk of bias.
(6) Other bias (checking for bias due to problems not covered by
(1) to (5) above)
We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;• high risk of other bias;• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book (Higgins 2011). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we con-
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sidered it was likely to impact on the findings. We explored the im-
pact of the level of bias through undertaking sensitivity analyses -
see Sensitivity analysis.
Assessment of the quality of the evidence using the GRADE
approach
We assessed the quality of the evidence using the GRADE approach,
as outlined in the GRADE Handbook in order to assess the quality
of the body of evidence relating to the following outcomes for the
main comparison (Planned early delivery versus expectant man-
agement (all women)):
1. Composite maternal outcome including maternal mortality
(death during pregnancy or up to 42 days after delivery) and se-
vere morbidity (eclampsia; cerebral vascular event; pulmonary
oedema, as defined by trial authors; severe renal impairment,
defined as a creatinine level greater than 125 μmol/l or a need
for dialysis or urine output less than 0.5 mL/kg/hour for four
hours unresponsive to hydration with two intravenous bolus-
es, or as defined by trial authors; liver haematoma or rup-
ture; liver failure, defined as the rapid impairment of synthet-
ic function and development of encephalopathy or as defined
by trial authors; haemolysis elevated liver enzymes and low
platelets (HELLP) syndrome; disseminated intravascular coagu-
lation (DIC); thromboembolic disease; and abruptio placentae,
defined as a retroplacental clot of more than 15% of the mater-
nal surface or as defined by trial authors).
2. Composite perinatal outcome including fetal or neonatal death
(within six weeks after the expected due date or as defined by tri-
al authors); grade III or IV intraventricular or intracerebral haem-
orrhage; necrotizing enterocolitis (NEC); acute respiratory dis-
tress syndrome (ARDS) or grade III/IV hyaline membrane dis-
ease; small-for-gestational age (growth below the 10th centile
or as defined by trial authors); and neonatal seizures.
3. Caesarean section.
4. Duration of hospital stay for mother after delivery.
5. Duration of hospital stay for fetus after delivery.
GRADEpro Guideline Development Tool was used to import data
from Review Manager 5 (RevMan 2014) in order to create ’Summa-
ry of findings’ tables. We produced a summary of the intervention
effect and a measure of quality for each of the above outcomes,
using the GRADE approach. The GRADE approach uses five consid-
erations (study limitations, consistency of effect, imprecision, indi-
rectness and publication bias) to assess the quality of the body of
evidence for each outcome. The evidence can be downgraded from
'high quality' by one level for serious (or by two levels for very se-
rious) limitations, depending on assessments for risk of bias, indi-
rectness of evidence, serious inconsistency, imprecision of effect
estimates or potential publication bias.
Measures of treatment e=ect
Dichotomous data
For dichotomous data, we present results as a summary risk ratio
(RR) with a 95% confidence interval (CI).
Continuous data
For continuous data, we used the mean difference if outcomes were
measured in the same way between trials. We used the standard-
ised mean difference to combine trials that measure the same out-
come, but using different methods. 
Unit of analysis issues
Cluster-randomised trials
We did not identify any cluster-randomised trials in the analyses.
If we had, we would have followed Chapter 16.3 of Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) to per-
form analysis of cluster-randomised trials. We would have calculat-
ed the intra-cluster correlation coefficient (ICC) and design effect.
We would have multiplied the standard error of the effect estimate
(from analysis ignoring clustering) by the square root of the design
effect. We would have performed meta-analysis using the inflate
variances and the generic inverse-variance method (Chapter 16.3.6
Higgins 2011).
Cross-over trials
Cross-over trials are inappropriate for this intervention.
Multi-armed trials
We did not identify any multi-armed trials. If we had, we would
have combined all relevant experimental intervention groups of
the study into a single group and all relevant control intervention
groups into a single control group when we analysed the data. If we
had considered one of the arms irrelevant, we would have exclud-
ed it from analysis.
Dealing with missing data
For included studies, we noted levels of attrition. We did not need
to explore the impact of including studies with high levels of miss-
ing data in the overall assessment of treatment effect by using sen-
sitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and analysed
all participants in the group to which they were allocated, regard-
less of whether or not they received the allocated intervention. The
denominator for each outcome in each trial was the number ran-
domised minus any participants whose outcomes are known to be
missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T2, I2 and Chi2 statistics. We regarded heterogeneity as substan-
tial if an I2 was greater than 30% and either a T2 was greater than
zero, or there was a low P value (less than 0.10) in the Chi2 test for
heterogeneity.
Assessment of reporting biases
There were fewer than 10 studies in the meta-analysis. In future up-
dates of this review, if there are 10 or more studies in a meta-analy-
sis, we will investigate reporting biases (such as publication bias)
using funnel plots. We will assess funnel plot asymmetry visually.
If asymmetry is suggested by a visual assessment, we will perform
exploratory analyses to investigate it.
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Data synthesis
We carried out statistical analysis using the Review Manager 5 soft-
ware (RevMan 2014). We used a fixed-effect meta-analysis for com-
bining data where it is reasonable to assume that studies are esti-
mating the same underlying treatment effect, i.e. where trials are
examining the same intervention, and the trials’ populations and
methods are judged sufficiently similar. If there was clinical hetero-
geneity sufficient to expect that the underlying treatment effects
differ between trials, or if we detected substantial statistical het-
erogeneity, we would have used a random-effects meta-analysis to
produce an overall summary, if an average treatment effect across
trials was considered clinically meaningful. We would have treat-
ed the random-effects summary as the average range of possible
treatment effects and we would have discussed the clinical impli-
cations of treatment effects differing between trials. If the average
treatment effect was not clinically meaningful, we would not com-
bine trials.
Where we use random-effects analyses, we present the results as
the average treatment effect with its 95% confidence interval, and
the estimates of  T2 and I2.
Subgroup analysis and investigation of heterogeneity
If we had identified substantial heterogeneity, we would have in-
vestigated it using subgroup analyses and sensitivity analyses. We
would have considered whether an overall summary is meaningful,
and if it was, we would have used random-effects analysis to pro-
duce it.
We carried out the following subgroup analyses:
1. Women at 34 weeks 0 days to 36 weeks 6 days of gestation versus
37 weeks 0 days to 38 weeks 6 days versus more then 39 weeks
of gestation.
2. Each gestational week.
3. Women with pre-eclampsia only versus women with gestation-
al hypertension (mild, not severe) only or pre-existing hyperten-
sion only.
We used the following primary outcomes in subgroup analysis.
1. composite maternal
2. composite perinatal outcome
Broekhuijsen 2015 has not yet published the composite outcomes
by gestational age, so we also carried out subgroup analysis using
the outcome respiratory distress syndrome.
We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2014). We reported the results of subgroup
analyses quoting the Chi2 statistic and P value, and the interaction
test I2 value.
Sensitivity analysis
We did not need to perform sensitivity analysis for primary out-
comes, as we did not identify substantial heterogeneity in the in-
cluded studies.
It was not indicated to perform sensitivity analyses for aspects of
the review that might affect the results; for example, where there is
a risk of bias associated with the quality of some of the included tri-
als; or to explore the effects of fixed-effect or random-effects analy-
ses for outcomes with statistical heterogeneity; and to explore the
effects of any assumptions made, such as the value of the ICC used
for cluster-randomised trials.
We would have used the following outcomes in sensitivity analyses.
1. Composite maternal outcome.
2. Composite perinatal outcome.
R E S U L T S
Description of studies
Results of the search
The search of Cochrane Pregnancy and Childbirth's Register re-
trieved 24 trial reports, and we found one additional report through
other sources. These reports corresponded to eight studies. Five
of these studies (22 reports) fulfilled the eligibility criteria for the
review (Broekhuijsen 2015; Hamed 2014; Koopmans 2009; Majeed
2014; Owens 2014). Two studies (two reports) were excluded (Ram-
rakhyani 2001; Tukur 2007), and one study (Shennan 2013) is ongo-
ing and will be eligible for inclusion when it is complete (See: Figure
1).
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Figure 1.   Study flow diagram.
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Included studies
We included five studies (involving 1819 women) in this review
(Broekhuijsen 2015; Hamed 2014; Koopmans 2009; Majeed 2014;
Owens 2014). See Characteristics of included studies.
Design
All five of the included studies were two-arm randomised con-
trolled trials, comparing planned early delivery with expectant
management for hypertensive disorders from 34 weeks to term.
Sample sizes
Two of the studies were large multicentre trials (Broekhuijsen 2015;
Koopmans 2009), which recruited 704 and 756 women respectively.
Hamed 2014 recruited 76 women at two hospitals. Two studies took
place in a single centre, recruiting 100 women (Majeed 2014), and
183 women (Owens 2014).
Setting
The two large multicentre trials were conducted in the Netherlands
(Broekhuijsen 2015; Koopmans 2009). Three smaller studies were
carried out in India (Majeed 2014), USA (Owens 2014), and Saudi
Arabia and Egypt (Hamed 2014).
Participants
The gestational age ranges of women eligible for the studies were
36 to 41 weeks (Koopmans 2009), 36 to 40 weeks (Majeed 2014), 34
to 37 weeks (Broekhuijsen 2015; Owens 2014), and 24 to 36 weeks
(Hamed 2014).
The type of hypertensive disorder included varied between stud-
ies: Koopmans 2009 and Majeed 2014 included pregnant women
with gestational hypertension or mild pre-eclampsia, Owens 2014
included women with mild pre-eclampsia only, Broekhuijsen 2015
recruited women with gestational hypertension, mild pre-eclamp-
sia or deteriorating chronic hypertension. Hamed 2014 was the on-
ly trial to concentrate on women with chronic hypertension (mild to
moderate, without proteinuria, diagnosed before 20 weeks' gesta-
tion or if the woman was known to be hypertensive before pregnan-
cy). Women were not eligible to participate in this study if they had
gestational hypertension or new onset of pre-eclampsia where pre-
viously normotensive, in contrast to Owens 2014 and Koopmans
2009 where only women who had newly identified hypertension
could participate.
Of the studies that included women with pre-eclampsia, they all ex-
cluded women with severe pre-eclampsia. Broekhuijsen 2015 and
Koopmans 2009 excluded women who had a diastolic blood pres-
sure ≥ 110 mmHg despite medication, a systolic blood pressure
≥ 170 mmHg despite medication, proteinuria ≥ 5 g per 24 hours,
eclampsia, HELLP syndrome, pulmonary oedema or cyanosis, olig-
uria less than 500 mL in 24 hours, renal disease, heart disease,
and severe pre-eclamptic complaints such as frontal headache or
ruptured membranes. Majeed 2014 excluded women if the systolic
blood pressure was above 160 mmHg, if the diastolic blood pres-
sure was above 110 mmHg or if there was more than 5 g proteinuria
per 24-hour collection. Owens 2014 excluded all that did not have
mild pre-eclampsia.
Studies had different inclusion and exclusion criteria for partici-
pants, some concerning factors that may be related to, or result
from, hypertensive disorders. For example, multiple pregnancies,
pre-existing diabetes, and suspected intrauterine growth restric-
tion. Broekhuijsen 2015 had the most inclusive eligibility criteria,
potentially meaning that the population of women recruited to
this study were more representative of women with hypertensive
disorders. Multiple pregnancies were excluded from Hamed 2014,
Koopmans 2009 and Owens 2014, but not excluded in Broekhuijsen
2015. In this study, 44 participants out of 703 had multifetal gesta-
tions (18 out of 352 randomised to planned early delivery, 26 out of
351 randomised to expectant monitoring), and the infant outcomes
were deemed present if at least one neonate was affected. Women
with diabetes mellitus were excluded from Hamed 2014, Koopmans
2009 and Owens 2014, but not excluded from Broekhuijsen 2015.
Women who had a previous caesarean section were excluded from
Hamed 2014 and Koopmans 2009, but not excluded from Broekhui-
jsen 2015. Babies with suspected intrauterine growth restriction
or small-for-gestational age were excluded from Koopmans 2009
and Owens 2014, but were not excluded from Broekhuijsen 2015.
Women taking antihypertensive medication were excluded from
Owens 2014, excluded if the medication was intravenous in Koop-
mans 2009, and eligible to participate in Broekhuijsen 2015. Majeed
2014 did not describe the exclusion criteria or detailed inclusion cri-
teria.
Interventions
Two studies compared an intervention group who had labour in-
duced before term: at 34 to 36 weeks' gestation (Broekhuijsen 2015)
and at 34 to 37 weeks (Owens 2014), with a comparison group who
were monitored until 37 weeks' gestation when induction began, if
labour had not started spontaneously. Three studies compared in-
duction of labour at term or closer to term: at 37 completed weeks
(Hamed 2014) and at 36 to 41 weeks (Koopmans 2009; Majeed 2014)
in the intervention group, with a comparison group who were mon-
itored until 41 weeks when induction began, if labour had not start-
ed spontaneously.
In the intervention groups, infants were delivered by induction of
labour, or by caesarean section if necessary. Three studies placed a
time limit on this intervention, within 12 hours (Owens 2014) or 24
hours (Broekhuijsen 2015; Koopmans 2009) of randomisation.
Labour was induced and augmented with amniotomy and oxytocin
(Broekhuijsen 2015; Hamed 2014; Koopmans 2009). If necessary
cervical ripening was stimulated with intracervical or intravaginal
prostaglandins or a balloon catheter (Broekhuijsen 2015; Koop-
mans 2009) or with vaginal misoprostol (Hamed 2014).
Women in the expectant management group were monitored as
outpatients (Hamed 2014), inpatients (Owens 2014), or in an inpa-
tient or outpatient setting depending on their condition (Broekhui-
jsen 2015; Koopmans 2009). Monitoring consisted of measur-
ing maternal blood pressure and screening of urine for protein
(Broekhuijsen 2015; Hamed 2014; Koopmans 2009), looking for
signs of disease progression with severe features of pre-eclampsia
(Owens 2014), mother's assessment of fetal movements and elec-
tronic fetal heart rate monitoring (Broekhuijsen 2015; Koopmans
2009), non-stress testing (Owens 2014), and ultrasound examina-
tion (Koopmans 2009). Majeed 2014 did not provide information on
the nature of the monitoring.
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Outcomes
The two largest trials (Broekhuijsen 2015; Koopmans 2009) report-
ed the composite outcome for maternal mortality and morbidity,
and a composite outcome for perinatal mortality and morbidity,
defined as the primary outcomes in this review. In addition, these
trials reported maternal and infant mortality and morbidity out-
comes individually. Maternal mortality was not reported by the oth-
er three trials (Hamed 2014; Majeed 2014; Owens 2014), and two tri-
als did not report perinatal mortality (Majeed 2014; Owens 2014).
All studies reported on disease progression, for example, the de-
velopment of severe hypertension, defined in a variety of ways
(Hamed 2014; Koopmans 2009; Owens 2014), eclampsia (Broekhui-
jsen 2015; Koopmans 2009), HELLP syndrome (Broekhuijsen 2015;
Koopmans 2009; Owens 2014), and acute renal failure (Majeed
2014). Adverse infant outcomes were reported for all trials except
Majeed 2014. These include possible consequences of early deliv-
ery for the infants, such as respiratory distress syndrome (Broekhui-
jsen 2015; Koopmans 2009; Owens 2014), and neonatal intensive
care unit admission (Broekhuijsen 2015; Hamed 2014; Koopmans
2009; Owens 2014).
Majeed 2014 was presented as a poster abstract, and the data were
therefore limited. We contacted the authors for additional infor-
mation, but have not received a reply. The most comprehensive
reporting of outcomes was by Broekhuijsen 2015 and Koopmans
2009, with both trials presented across multiple published reports.
Funding sources
Two studies (Broekhuijsen 2015; Koopmans 2009) were funded
by ZonMw, the Netherlands Organisation for Health Research and
Development. Hamed 2014 and Owens 2014 were both funded
through their affiliated universities: Qassim University and the Uni-
versity of Mississippi Medical Centre, respectively. As Majeed 2014
was presented as a poster abstract, with limited information given,
it is not clear who provided funding for this study.
Declarations of interest
None of the study authors declared any conflicts of interest. This
was not mentioned in Majeed 2014.
Excluded studies
We excluded two studies (two reports); one because it was not a
randomised controlled trial, with group allocation based on gesta-
tional age at presentation (Ramrakhyani 2001), and the other com-
pared two methods of planned early delivery: caesarean section
and induction with vaginal misoprostol (Tukur 2007). See Charac-
teristics of excluded studies.
Ongoing studies
We found one ongoing study (Shennan 2013). This trial compares
planned early delivery with monitoring until induction at 37 weeks'
gestation, for pregnant women with pre-eclampsia between 34 and
37 weeks of gestation. According to the protocol, recruitment start-
ed in April 2014, and it was anticipated that it will take approximate-
ly three years to recruit 900 women. See Characteristics of ongoing
studies.
Risk of bias in included studies
Assessment of the methodological quality of the included studies
was based on risk of bias in relation to selection bias (method of
randomisation and allocation concealment), performance bias, de-
tection bias, attrition bias (loss of participants from the analyses)
and reporting bias. A summary of 'Risk of bias' assessments for each
study, and for included trials overall, are set out in Figure 2 and Fig-
ure 3.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
Generation of the randomisation sequence
Three studies reported using a computerised or web-based ran-
dom-number generator to generate the randomisation sequence,
which we judged were at low risk of bias (Broekhuijsen 2015;
Hamed 2014; Koopmans 2009). We judged the remaining two stud-
ies to be at unclear risk of bias: Owens 2014 described using strati-
fied and random permuted blocks of two but did not describe how
the randomisation sequence was generated, and Majeed 2014 did
not mention the method for determining the randomisation se-
quence.
Allocation concealment
In two of the studies, the method for concealing group allocation
at the point of randomisation was not clear (Hamed 2014; Majeed
2014). Three studies were at low risk of bias: Owens 2014 concealed
allocation in sealed envelopes, and the web-based central alloca-
tion of Broekhuijsen 2015 and Koopmans 2009 concealed their al-
location.
Blinding
The blinding of women and health professionals was not possible
for this intervention. This may have had an effect on other treat-
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ment decisions. All included studies have consequently been as-
sessed as high risk of bias due to lack of blinding.
Incomplete outcome data
We considered the risk of bias to be low in Broekhuijsen 2015,
Hamed 2014 and Koopmans 2009, as all women were accounted for
and there was little or no attrition. The number of women allocated
to each group was not reported by Majeed 2014, so we judged the
risk of bias to be unclear as we cannot assess whether data for all
women are reported. There was some attrition from Owens 2014,
and the data were not presented as intention-to-treat, so we con-
sidered that the risk of bias is also unclear for this trial.
Selective reporting
Protocols were available for Broekhuijsen 2015, Koopmans 2009
and Owens 2014. All prespecified outcomes were reported for these
trials, so we judged these to be at a low risk of reporting bias. Re-
porting appeared to be good in Hamed 2014, however no proto-
col was available to assess whether all prespecified outcomes were
reported, so risk of bias was unclear. Majeed 2014 was assessed
from a poster-presentation abstract, which only reported signifi-
cant findings, and was therefore at high risk of bias.
Other potential sources of bias
Owens 2014 was stopped early due to a change in hospital policy,
at 74% of the enrolment target, leaving the study underpowered to
demonstrate statistically significant differences, with unclear im-
plications for the risk of other bias. The baseline characteristics of
women assigned to the planned delivery and expectant monitor-
ing groups appear to be similar in all studies, so there is low risk of
other potential sources of bias for Broekhuijsen 2015, Hamed 2014,
Koopmans 2009, and Majeed 2014.
E=ects of interventions
See: Summary of findings for the main comparison Planned early
delivery versus expectant management for hypertensive disorders
from 34 weeks' gestation to term
Planned early delivery versus expectant management
See Summary of findings for the main comparison. We included five
studies, involving 1819 women.
Primary outcomes
Two studies reported thecomposite maternal outcome, includ-
ing maternal mortality and severe morbidity (Broekhuijsen
2015; Koopmans 2009). There was a lower risk of these severe ad-
verse outcomes for women randomised to planned early delivery
(risk ratio (RR) 0.69, 95% confidence interval (CI) 0.57 to 0.83, two
studies, 1459 women, evidence graded high, Analysis 1.1). There
were no clear differences between groups based on our subgroup
analysis by gestational age, gestational week or condition (see
Analysis 2.1; Analysis 3.1; Analysis 4.1).
The same two studies also reported the composite perinatal out-
come (including fetal or neonatal death and serious morbidi-
ty). There was not enough information to draw any conclusions
about the effects on neonatal mortality and serious morbidity.
Meta-analysis was not possible, due to substantial heterogeneity
(I2 = 87%, Tau2 = 0.98) for this outcome between these two stud-
ies (1459 infants, Analysis 1.2). It is worth noting that Broekhuijsen
2015 found that infants in the planned early delivery group had a
higher risk of respiratory distress syndrome than those in the ex-
pectant management group (RR 3.32, 95% CI 1.35 to 8.18, 703 in-
fants, Analysis 2.2) with planned early delivery taking place at 34 to
37 weeks' gestation. However Koopmans 2009 showed no evidence
of differences in composite infant mortality and morbidity (RR 0.77,
95% CI 0.46 to 1.28, 756 infants, Analysis 2.3) with planned early de-
livery taking place later, at 36 to 41 weeks' gestation. There were
no clear differences between groups based on our subgroup analy-
sis by gestational age or gestational week (see Analysis 2.3; Analy-
sis 3.2; Analysis 3.3). However Broekhuijsen 2015 have not yet pub-
lished the composite outcomes by gestational age, so any possible
adverse effects on infants born at the earliest gestations have not
yet been explored.
Secondary outcomes
Maternal
There were no incidences of maternal mortality in the two stud-
ies that reported it (1457 women, Analysis 1.3). We found no clear
differences between delivery and expectant management for the
number of women experiencing eclampsia (RR 0.20, 95% CI 0.01 to
4.14, 1459 women, two studies, Analysis 1.4). There were no events
reported for pulmonary oedema (703 women, one study, Analy-
sis 1.5). Women who were assigned planned early delivery had a
lower risk of severe renal impairment (RR 0.36, 95% CI 0.14 to
0.92, 100 women, one study, Analysis 1.6), and HELLP syndrome
(RR 0.40, 95% CI 0.17 to 0.93, 1628 women, three studies, Analy-
sis 1.7) than women assigned to expectant management. We found
no clear differences between planned early delivery and expectant
management for the number of women experiencing thromboem-
bolic disease (RR 1.67, 95% CI 0.22 to 12.58, 1459 women, two stud-
ies, Analysis 1.8), abruptio placentae (RR 0.64, 95% CI 0.17 to 2.34,
1535 women, three studies, Analysis 1.9), or postpartum haemor-
rhage (RR 0.88, 95% CI 0.57 to 1.35, 741 women, one study, Analysis
1.10).
There was high heterogeneity between studies for women devel-
oping severe hypertension (I2 = 79%, Tau2 = 0.83). There was not
enough information to draw any conclusions about the effects on
severe hypertension (995 women, three studies, Analysis 1.11). Two
studies (919 women) reporting this outcome found that planned
early delivery was less likely to result in the progression to severe
hypertension, while one study (74 women) found no difference. The
study that found no difference had recruited pregnant women with
chronic hypertension (Hamed 2014), while the women in the other
two studies had mild pre-eclampsia (Owens 2014), gestational hy-
pertension or mild pre-eclampsia (Koopmans 2009).
We found no clear differences between planned early delivery and
expectant management for caesarean section (RR 0.91, 95% CI
0.78 to 1.07, 1728 women, four studies, evidence graded moder-
ate, Analysis 1.12), assisted delivery (ventouse/forceps) (RR 0.93,
95% CI 0.70 to 1.24, 1459 women, two studies, Analysis 1.13), or en-
dometritis (maternal morbidity of caesarean section) (RR 0.75,
95% CI 0.17 to 3.35, 756 women, one study, Analysis 1.14). There
were no events reported for uterine rupture (maternal morbidity
related to induction of labour) (756 women, one study, Analysis
1.15). We found no clear differences between planned early delivery
and expectant management for maternal admission to a high care
or intensive care unit (RR 0.41, 95% CI 0.16 to 1.07, 708 women,
one study, Analysis 1.16).
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Women's experiences and views on the interventions were not
reported in any of the included studies. However, Koopmans 2009
assessed women's health-related quality of life after planned early
delivery or expectant management. They administered the Short-
Form (SF-36), European Quality of Life (EuroQoL 6D3L), Hospi-
tal Anxiety and Depression Scale (HADS), and Symptom Checklist
(SCL-90). Measurements were at baseline, six weeks postpartum
and six months postpartum. They found no clear difference in these
measures of health-related quality of life. (The numeric results are
not presented in this review, because the outcomes do not corre-
spond to those prespecified in the protocol. However, as these are
important issues we have included this narrative summary of the
results).
Several of the outcomes for this review were not reported by tri-
al authors: cerebrovascular event, liver haematoma or rupture,
liver failure as defined above, dissemination intravascular co-
agulation, and antepartum haemorrhage.
Fetal and neonatal
One study reportedfetal death, with no events (756 infants, Analy-
sis 1.17). There were very few events, and therefore not enough in-
formation to see if there was a difference in neonatal death (RR
2.00, 95% CI 0.19 to 21.14, 1535 infants, three studies, Analysis 1.18)
and grade III or IV intraventricular or intracerebral haemor-
rhage (RR 6.92, 95% CI 0.36 to 133.41, 674 infants, one study, Analy-
sis 1.19). We found no clear difference in the numbers of infants
with nectrotising enterocolitis (RR 0.98, 95% CI 0.14 to 6.89, 1338
infants, two studies, Analysis 1.20). Babies allocated to planned
early delivery had a higher risk of acute respiratory distress syn-
drome or grade III/IV hyaline membrane disease (RR 2.24, 95% CI
1.20 to 4.18, 1511 infants, three studies, Analysis 1.21). There was no
clear difference between groups assigned to planned early delivery
or expectant monitoring for small-for-gestational age as defined
by trial authors (RR 1.58, 95% CI 0.89 to 2.79, 1001 infants, three
studies, Analysis 1.22), neonatal seizures (RR 3.97, 95% CI 0.45 to
35.30, 699 infants, one study, Analysis 1.23), Apgar score less than
seven at five minutes (RR 1.11, 95% CI 0.60 to 2.05, 1454 infants,
two studies, Analysis 1.24), and cord blood pH less than 7.1 or as
defined by trial authors (RR 0.58, 95% CI 0.31 to 1.09, 1145 infants,
two studies, Analysis 1.25). In the one study that reported surfac-
tant use, no infants required it (639 infants, Analysis 1.26). Babies in
the group allocated to planned early delivery were more likely to be
admitted to neonatal intensive care unit or high care unit than
those allocated to expectant management (RR 1.65, 95% CI 1.13
to 2.40, 1585 infants, four studies, Analysis 1.27). Intubation and
mechanical ventilation or continuous positive airway pressure
support was not reported in any of the included studies. There was
a substantial difference in the incidence of early neonatal sepsis
between the two studies that reported it, so results have not been
pooled (1455 infants, two studies, Analysis 1.28).
Use of health-service resources
There was no clear difference in the duration of hospital stay af-
ter delivery for mother (mean difference (MD) -0.16 days, 95% CI
-0.46 to 0.15; 925 women, two studies, evidence graded moderate,
Analysis 1.29), and no clear difference in the duration of hospital
stay after delivery for baby (MD -0.20 days, 95% CI -0.57 to 0.17,
756 infants, one study, evidence graded moderate, Analysis 1.30).
Economic outcomes
The costs to health service resources: short-term and long-term
for both mother and baby and costs to the woman, her family,
and society were not reported in the included studies.
D I S C U S S I O N
Summary of main results
We included five studies involving 1819 women, comparing
planned early delivery versus expectant management for hyperten-
sive disorders from 34 weeks to term.
Fewer women who had hypertensive disorders of pregnancy expe-
rienced severe adverse outcomes (composite maternal mortality
and severe morbidity) when they were allocated to planned early
delivery. Planned early delivery was also associated with lower lev-
els of HELLP syndrome and severe renal impairment. There was no
clear difference in any of the other maternal outcomes reported by
the included studies.
There was not enough information to draw any conclusions about
the effects on neonatal mortality and severe morbidity, as there
were limited data assessing all hypertensive disorders as one
group. Planned early delivery was associated with higher levels of
respiratory distress syndrome, and NICU admission. There was no
clear difference for other infant outcomes reported by the included
studies.
No difference was shown between planned early delivery and ex-
pectant management in the proportion of women needing a cae-
sarean section, and in the duration of hospital stay after delivery for
mother or baby.
(See Summary of findings for the main comparison.)
Overall completeness and applicability of evidence
The studies included in this review addressed the objective, which
was to determine the risks and benefits of expectant manage-
ment versus planned early delivery for the hypertensive disor-
ders of pregnancy after 34 weeks gestation. The management of
pre-eclampsia diagnosed before 34 weeks is described in another
Cochrane Review (Churchill 2013). The majority of women includ-
ed in this review had mild pre-eclampsia and gestational hyperten-
sion, with fewer women having chronic hypertension. Most of the
women included came from the Netherlands, with smaller num-
bers from India, USA and Saudi Arabia, making the review globally
applicable. The results are applicable to general obstetric practice
when the hypertensive disorders of pregnancy are considered to-
gether, but an individual patient meta-analysis may provide more
answers as it would allow for more statistical power when review-
ing the different types of hypertensive disorders in pregnancy.
Quality of the evidence
Two fairly large, well-designed trials contributed the majority of the
evidence to this review (Broekhuijsen 2015; Koopmans 2009). Due
to the nature of the intervention, no studies attempted to blind par-
ticipants or clinicians to group allocation. We did not downgrade
studies for this; however, women and staL would have been aware
of the intervention and this may have affected aspects of care and
decision-making, for example, whether to carry out a caesarean
section.
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We graded the level of evidence as high (composite maternal mor-
tality and morbidity), moderate (caesarean section, duration of
hospital stay after delivery for mother, and duration of hospital stay
after delivery for baby), or low (composite infant mortality and mor-
bidity) (see Summary of findings for the main comparison). Where
the evidence was downgraded, it was mostly because the CIs were
wide, crossing both the line of no effect and appreciable benefit or
harm.
Potential biases in the review process
The assessment of risk of bias involves subjective judgements. This
potential limitation is minimised by following the procedures in the
Cochrane Handbook for Systematic Reviews of Interventions (Hig-
gins 2011), with review authors independently assessing studies
and resolving any disagreement through discussion, and if required
involving a third assessor in the decision.
Agreements and disagreements with other studies or
reviews
The findings of this review show that planned early delivery for hy-
pertensive disorders of pregnancy are associated with less severe
maternal adverse outcomes. This analysis looks at all the hyperten-
sive diseases, namely chronic hypertension, gestational hyperten-
sion and mild pre-eclampsia as one group. The National Institute
for Health and Clinical Excellence guidelines on hypertension in
pregnancy: diagnosis and management (NICE 2010), the American
College of Obstetricians and the Society for Maternal-Fetal Medi-
cine and Gynecologists Committee opinion number 560 on med-
ically indicated late-preterm and early term deliveries (ACOG No.
560 2013) and the Society of Obstetric Medicine of Australia and
New Zealand guideline for the management of hypertensive disor-
ders of pregnancy (Lowe 2014) set different gestational ages for de-
livery based on the hypertensive condition.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For hypertensive disorders as a group, based on the limited data
available for this review, planned early delivery appears to be bet-
ter for the mother after 34 weeks' gestation. However, it is unclear
whether planned early delivery increases risks for the baby, espe-
cially at earlier gestations, and more data are needed to guide prac-
tice. It is also unclear whether planned early delivery is advisable
for different hypertensive conditions. Further studies are needed
to look at the individual conditions before this is implemented into
clinical practice.
Implications for research
Further studies are needed to look at the different types of hy-
pertensive diseases and the optimal timing of delivery for these
conditions. These studies should include the maternal outcomes
of mortality and severe morbidity like eclampsia, a cerebral vas-
cular event, pulmonary oedema, severe renal impairment, a liver
haematoma or rupture, liver failure, HELLP syndrome, DIC, throm-
boembolic disease and abruptio placentae. Perinatal outcomes
that should be included are fetal or neonatal death, grade III or
IV intraventricular or intracerebral haemorrhage, NEC, ARDS or
grade III/IV hyaline membrane disease, small-for-gestational age
and neonatal seizures. The outcomes of the incidence of caesare-
an section, duration of hospital stay after delivery for mother and
duration of hospital stay after delivery for baby should also be in-
cluded.
An individual patient meta-analysis on the data currently available
would provide further information on the outcomes of the different
types of hypertensive disease encountered in pregnancy.
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Characteristics of included studies [ordered by study ID]
 
Methods 2-arm multicentre randomised controlled trial.
Participants Setting: 51 hospitals in the Netherlands. June 2009 to March 2013.
Inclusion criteria: pregnant women (singleton or multiple pregnancies), 34+0-36+6 weeks' gestation,
who had gestational hypertension, mild pre-eclampsia, or deteriorating chronic hypertension. Ges-
tational hypertension: diastolic blood pressure ≥ 100 mmHg on 2 occasions at least 6 hours apart in a
woman who was normotensive until at least 20 weeks GA. Mild PE: diastolic blood pressure > 90 mmHg
on 2 occasions at least 6 hours apart in a woman who was normotensive until at least 20 weeks GA plus
proteinuria (> 300 mg total protein in a 24-hour urine collection or > 30 in a spot urine protein:creati-
nine ratio). Chronic hypertension: diastolic blood pressure ≥ 90 mmHg on 2 occasions at least 6 hours
apart, diagnosed before 20 weeks of gestation.
Women with singleton or multiple pregnancies are eligible, independent of the position of the fetus (i.e.
cephalic or breech). Neither diabetes mellitus, nor small-for-gestational age nor a history of caesarean
section are exclusion criteria.
Exclusion criteria: diastolic blood pressure ≥ 110 mmHg despite medication, systolic blood pressure ≥
170 mmHg despite medication, proteinuria ≥ 5 g per 24 hours, eclampsia, HELLP syndrome, pulmonary
oedema or cyanosis, oliguria < 500 mL in 24 hours, renal disease, heart disease, HIV-positive, non-reas-
suring fetal heart rate, absent flow or reversed flow in the umbilical artery, fetal abnormalities includ-
ing an abnormal karyotype, ruptured membranes and severe pre-eclamptic complaints such as frontal
headaches
Interventions Experimental intervention: planned early delivery with an induction of labour started within 24 hours
after randomisation
If vaginal delivery was not contraindicated and the cervix was considered favourable an amniotomy
was performed and augmentation with oxytocin was used if indicated. In cases of unfavourable cervix,
induction was preceded with cervical ripening according to the local protocol. Prostaglandins were
not administered to women with a history of caesarean section and in these cases a Foley catheter, fol-
lowed by amniotomy and oxytocin were used instead
Where vaginal delivery is contraindicated (e.g. breech presentation or a history of 2 caesarean sections)
the woman will be delivered by caesarean section within 24 hours after randomisation. 353 women
randomised (1 woman subsequently withdrew)
Control/Comparison intervention: expectant monitoring until 37 weeks of GA. Monitored until the
onset of spontaneous delivery. If labour had not started at 37 + 0 weeks, labour was induced. Monitor-
ing consisted of the mother’s assessment of fetal movements, electronic fetal heart rate monitoring at
least twice a week and maternal blood pressure measurement and screening of urine for protein. Inter-
Broekhuijsen 2015 
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vention was recommended if the fetal or maternal condition did not justify expectant monitoring any
more, similar to the exclusion criteria of the trial. 351 women randomised
Outcomes Composite adverse maternal outcome (eclampsia, HELLP syndrome, pulmonary oedema, thromboem-
bolic disease, placental abruption, and/or maternal death), neonatal morbidity, neonatal death
Funding source This trial was funded by ZonMw, The Netherlands Organisation for Health Research and Development,
programme Doelmatigheidsonderzoek (Health Care Efficiency Research, grant 171102012).
Declarations of interest No conflicts of interests declared.
Notes Registered with the Netherlands Trial Register (NTR1792)
HW emailed Dr Koopmans on 6/8/15 to ask if the composite infant outcome by gestation at randomisa-
tion is available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was done with a web-based system by random permuted
blocks with variable block size (range 2 - 4), stratified by centre
Allocation concealment
(selection bias)
Low risk Central allocation of women concealed allocation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label study: “it is impossible to blind the healthcare workers and pa-
tients involved for the strategy to which the woman is allocated”
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome assessment does not appear to have been blinded. Data were en-
tered into a web-based case report form, coded to ensure confidentiality
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All women are accounted for. 1 woman withdrew after being randomised to
planned early delivery. Analysis was by intention-to-treat in Broekhuijsen
2014, but not in Broekhuijsen 2015. A subset of 200 women received quality-of-
life questionnaires. The results of this subset of women are not included in this
review
Selective reporting (re-
porting bias)
Low risk All outcomes that were prespecified in the protocol were reported
Other bias Low risk The baseline characteristics of women randomly assigned to planned deliv-
ery and expectant monitoring appear to be similar. “When compared with
randomly assigned women, women who declined to be randomly assigned
more often finished higher education, were more often non-smokers, were
more often nulliparous, and had a lower GA. Otherwise, baseline character-
istics were much the same in randomly assigned and not randomly assigned
women”. This may affect the generalisability of the results of this study, but is
not a source of bias per se
Broekhuijsen 2015  (Continued)
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Participants Setting: Saudi Arabia and Egypt. Maternity-Children Hospital, Al-Qassim region, Saudi Arabia and
Women’s Health Center, Assiut University, Egypt. April 2012 - October 2013
Inclusion criteria: women with a singleton pregnancy with mild to moderate essential chronic hyper-
tension without proteinuria. GA at recruitment 24 - 36 weeks. Diastolic blood pressure between 90 and
110 mmHg and/or systolic pressure between 140 and 160 mmHg on 2 occasions at least 6 hours apart
in the first half of pregnancy or if the woman was known to be hypertensive before pregnancy
Exclusion criteria: severe chronic hypertension (blood pressure ≥ 160/110 mmHg); gestational hyper-
tension; new onset pre-eclampsia in a previously normotensive woman; secondary hypertension (ex-
cluded by examination and relevant investigations such as kidney function tests, urine analysis, ab-
dominal ultrasound, renal artery Doppler, urinary catecholamine, and autoimmune serologic profile);
target organ damage excluded by opthalmological fundus examination, and renal and cardiac assess-
ment; and medical or obstetric risk factors such as malpresentation at recruitment, placenta previa,
uterine scar, fetal anomalies, or pregestational diabetes mellitus
Interventions Experimental intervention: delivery at 37 completed weeks, provided that no maternal or fetal com-
plications demanded elective preterm labour. If the Bishop score was > 8, labour was induced by oxy-
tocin infusion and amniotomy. If the Bishop score was 8 or less, cervical ripening was induced by vagi-
nal misoprostol at a dose of 50 µg every 6 hours up to a maximum of 200 µg, followed by an oxytocin in-
fusion and amniotomy
Women continued any antihypertensive drugs that they used before recruitment, and the dose was
monitored to achieve control of blood pressure. 38 women were randomised
Control/Comparison intervention: expectant management until the spontaneous onset of labour or
41 gestational weeks
Monitored as outpatients for blood pressure measurement with dipstick screening for proteinuria 2 - 3
times per week. Hospitalised during the initial evaluation and if maternal or fetal complications devel-
oped.
Women continued any antihypertensive drugs that they used before recruitment, and the dose was
monitored to achieve control of blood pressure. 38 women were randomised
Outcomes Superimposed pre-eclampsia, severe hypertension, preterm delivery, placental abruption, oligohy-
dramnios, intrauterine growth restriction, perinatal mortality, GA at delivery, birthweight, caesarean
section, neonatal intensive care unit admission
Funding source The authors acknowledge the Deanship of Scientific Research in Qassim University for financial sup-
port for this work through an official grant (research number 1681/1433-1434).
Declarations of interest No conflicts of interests declared.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Eligible women were randomised by a computer-generated table, and allocat-
ed by 1:1 ratio to group A or group B
Allocation concealment
(selection bias)
Unclear risk No description of allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel was not possible. This may have had an
effect on other treatment decisions
Hamed 2014  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome assessment does not appear to have been blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No loss to follow-up reported on flow diagram
Selective reporting (re-
porting bias)
Unclear risk Reporting appeared to be good; however no protocol was available to assess
whether all prespecified outcomes were reported
Other bias Low risk The groups appear to be comparable at baseline
Hamed 2014  (Continued)
 
 
Methods 2-arm multicentre randomised controlled trial
Participants Setting: 38 hospitals (6 academic and 32 non-academic) in Netherlands between October 2005 and
March 2008
Inclusion criteria: women with a singleton pregnancy at 36 (0 days) - 41 weeks (0 days) gestation who
had gestational hypertension or mild pre-eclampsia. Gestational hypertension was defined as diastolic
blood pressure of 95 mmHg or higher measured on 2 occasions at least 6 hours apart. Mild pre-eclamp-
sia was defined as diastolic blood pressure of 90 mmHg or higher measured on 2 occasions at least 6
hours apart, combined with proteinuria (2 or more occurrences of protein on a dipstick, > 300 mg total
protein within a 24-hour urine collection, or ratio of protein to creatinine > 30 mg/mmol)
Exclusion criteria: severe gestational hypertension or severe pre-eclampsia, defined as systolic blood
pressure of 170 mmHg or higher, diastolic blood pressure of 110 mmHg or higher, or proteinuria of 5
g or higher per 24 hours. Other exclusion criteria: pre-existing hypertension treated with antihyper-
tensive drugs, diabetes mellitus, gestational diabetes needing insulin treatment, renal disease, heart
disease, previous caesarean section, HELLP syndrome, oliguria of less than 500 mL per 24 hours, pul-
monary oedema or cyanosis, HIV seropositivity, use of intravenous antihypertensive drugs, fetal anom-
alies, suspected intrauterine growth restriction, abnormalities detected during fetal-heart-rate moni-
toring, non-vertex position
Interventions Experimental intervention: induction of labour within 24 hours of randomisation. If the Bishop score
was > 6, labour was induced with amniotomy and if needed augmentation with oxytocin. If the Bish-
op score was ≤ 6, cervical ripening was stimulated with intracervical or intravaginal prostaglandins or
a balloon catheter. Use of oxytocin or prostaglandins depended on local protocols. 377 women ran-
domised.
Control/Comparison intervention: expectant monitoring. They were monitored until the onset of
spontaneous delivery, in hospital or outpatient setting, depending on the condition of the woman with
frequent blood pressure measurements and testing of urine for protein of the mother. Fetal monitoring
included movements as reported by the mother, electronic fetal-heart-rate monitoring and ultrasound
examination. Induction of labour was recommended if the systolic blood pressure was 170 mmHG or
higher or if the diastolic blood pressure was 110 mmHg or higher, if there was proteinuria of 5 g or high-
er per 24 hours, if eclampsia developed, if HELLP syndrome was present, if there was suspected fetal
distress, if prelabour rupture of membranes lasting more than 48 hours occurred, if there was meconi-
um-stained amniotic fluid, or a fetus with GA beyond 41 weeks. 379 women randomised.
Outcomes Composite of poor maternal outcome which included maternal mortality, maternal morbidity (eclamp-
sia, HELLP syndrome, pulmonary oedema, thromboembolic disease, and placental abruption), pro-
gression to severe hypertension or proteinuria and a major postpartum haemorrhage (> 1000 mL blood
loss)
Koopmans 2009 
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Funding source This trial was funded by ZonMw, the Netherlands organisation for health research and development,
programme Doelmatigheidsonderzoek (grant number 945-06-553).
Declarations of interest No conflicts of interests declared.
Notes HW emailed Dr Koopmans on 6/8/15 to ask if the mean and standard deviation are available for contin-
uous variables (e.g. duration of hospital stay after delivery, economic outcomes), reported in publica-
tions as median and IQR. Also, whether health-related quality of life measures are available in a form
that could be used in the review
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Good random sequence generation. Block randomisation with a variable
block size of 2 - 8. Web-based application used to stratify for centre, parity,
and hypertensive-related disease (gestational hypertension or pre-eclampsia).
Women were randomly allocated in a 1:1 ratio to receive either induction of
labour or expectant monitoring
Allocation concealment
(selection bias)
Low risk Central allocation using a web-based application.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk “in this open-label trial, masking of participants, obstetricians and outcome
assessors was not possible for allocation of the randomisation number or in-
tervention.”
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk “in this open-label trial, masking of participants, obstetricians and outcome
assessors was not possible for allocation of the randomisation number or in-
tervention.”
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The analysis was by intention-to-treat. Data are reported for all randomised
women.
Fewer women participated in the quality of life study (questionnaires were not
available for 217 women. 48/539 did not respond to the questionnaire, giving a
91% response rate)
Selective reporting (re-
porting bias)
Low risk All outcomes that were prespecified in the protocol were reported
Other bias Low risk The groups appear to be comparable at baseline. The report states that the
funder "had no role in study design, data collection, data analysis, data inter-
pretation, writing of the report, or the decision to submit the paper for publi-
cation"
Koopmans 2009  (Continued)
 
 
Methods 2-arm randomised controlled trial.
Participants Setting: May 2011 to April 2012 in Government Medical College, Kolkata, India
Inclusion criteria: pregnant women at 36 - 40 weeks' gestation, with mild pre-eclampsia/gestational
hypertension without proteinuria. A diagnosis of gestational hypertension was made if systolic blood
pressure ≥ 140 or diastolic blood pressure ≥ 90 mmHg for the first time during pregnancy without pro-
Majeed 2014 
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teinuria. A diagnosis of mild pre-eclampsia was made if systolic blood pressure was 140 - 159 mmHg
and diastolic blood pressure is 90 - 109 mmHg accompanied by proteinuria of > 0.3 g to < 5 g/24 hours.
Exclusion criteria: not described
Interventions Experimental intervention: induction of labour (no further information)
Control/Comparison intervention: expectant management (no further information)
100 women were randomised. The number of women in each group is not stated, so we assume it was
50, as women were randomised in a 1:1 manner
Outcomes Maternal: severe hypertension, severe proteinuria, eclampsia, placental abruption, HELLP syndrome,
disseminated intravascular coagulation, postpartum haemorrhage, retinal haemorrhage, pulmonary
oedema. Caesarean section. Admission to delivery interval. Hospital stay. 
Perinatal: asphyxia, respiratory distress syndrome, very low birthweight, meconium aspiration, me-
chanical ventilation, neonatal intensive care unit admission
Funding source No information given - abstract only.
Declarations of interest No information given - abstract only.
Notes This trial report was in abstract form only (which could explain the paucity of detail).
HW emailed Professor Singh on 30/4/15 and 5/8/15, asking:
How many women were recruited to each group?
Please would you describe the process of randomisation and group allocation.
Would you be able to provide data on any of the following outcomes (review outcomes listed).
No reply received at present.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk States that women were “randomized in 1:1 manner”, but no information on
the method
Allocation concealment
(selection bias)
Unclear risk No description
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk It was not possible to blind participants and personnel to whether they had
been assigned to induction of labour or expectant management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No blinding of outcome assessment mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The number of women allocated to each group is not reported, so it is not pos-
sible to assess whether data for all women have been reported
Selective reporting (re-
porting bias)
High risk Only outcomes with significant differences between groups were reported
Majeed 2014  (Continued)
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Other bias Low risk The report states that the groups were comparable at baseline
Majeed 2014  (Continued)
 
 
Methods 2-arm randomised control trial.
Participants Setting: women admitted to The Wiser Hospital for Women and Infants at the University of Mississippi
Medical Center (UMMC) from March 2002 to June 2009
Inclusion criteria: pregnant women with mild pre-eclampsia, 34 - 37 weeks (with estimated fetal
weight > 2000 g), no other maternal-fetal-pregnancy complications. (ACOG 2002 criteria for mild pre-
eclampsia.) No maternal or fetal contraindications to conservative management. Age 18 - 50.
Exclusion criteria: non-gestational diabetes, chronic hypertension, severe pre-eclampsia, non-reas-
suring fetal assessment intrauterine growth restriction fetal anomalies, multiple gestation, premature
preterm rupture of membranes, placenta previa, unexplained vaginal bleeding, antihypertensive use,
current gestation poor dating, contraindication to conservative management, active labour at admis-
sion
Interventions Experimental intervention: planned early delivery via induction of labour or caesarean delivery with-
in 12 hours of randomisation
All study participants were treated with magnesium sulphate prophylaxis intrapartum and immediate-
ly postpartum
97 women were randomised, 3 were subsequently excluded for not meeting the inclusion criteria
Control/Comparison intervention: inpatient expectant management, to 37 weeks' gestation unless
there was spontaneous onset of labour or rupture of membranes, suspected placental abruption, de-
velopment of severe PE of fetal compromise. All study participants were treated with magnesium sul-
phate prophylaxis intrapartum and immediately postpartum
86 women were randomised (11 were subsequently excluded for not meeting the inclusion criteria (7),
voluntarily withdrawing from the study (1), and leaving the hospital (3))
Outcomes Primary: maternal morbidity, mortality, and development of severe pre-eclampsia. Secondary: major
neonatal morbidities and mortality
Funding source Funded by Division of Maternal-fetal Medicine in the Department of Obstetrics and Gynaecology, Uni-
versity of Mississippi Medical Centre.
Declarations of interest No conflicts of interests declared.
Notes ClinicalTrials.gov: NCT00789919
HW emailed Professor Owens on 11/8/15, asking how the random sequence was generated, if compos-
ite maternal and infant outcomes were available, and for duration of infant stay after delivery. No re-
sponse was received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised using stratified and random permuted blocks of 2 in consecutive-
ly numbered opaque envelopes. However, the sequence generation was not
described
Owens 2014 
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Allocation concealment
(selection bias)
Low risk Opaque envelopes concealed allocation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk It was not possible to blind participants and personnel to whether they had
been assigned to induction of labour or expectant management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No blinding of outcome assessment mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The analysis was not intention-to-treat. 3 (out of 97) participants leF the
planned early delivery group, and 11 (out of 86) leF the expectant manage-
ment group, and were excluded from the analyses
Selective reporting (re-
porting bias)
Low risk The outcomes prespecified in the protocol were reported
Other bias Unclear risk The study was stopped early, at 74% of the enrolment target, when hospital
policy changed to discourage inpatient hospitalisation for "uncomplicated
mild preterm preeclampsia”. This leF the study underpowered to demonstrate
statistically significant differences
Owens 2014  (Continued)
GA gestational age
HELLP: haemolysis, elevated liver enzymes and low platelet count
IQR: interquartile range
PE: pre-eclampsia
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ramrakhyani 2001 Not a randomised controlled trial. No randomisation. Group allocation based on gestational age at
presentation
Tukur 2007 Comparing planned early delivery by caesarean section with planned early delivery by induction
with vaginal misoprostol
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title PHOENIX - Pre-eclampsia in HOspital: Early iNductIon or eXpectant management
Methods 2-arm trial. “randomly allocated”, no description of method of randomisation in trial registration
Participants Pregnant women with pre-eclampsia between 34 and 37 weeks of gestation
Interventions Experimental intervention: planned early birth. Induced within 48 hours of group allocation.
Control/Comparison intervention: monitored in hospital. Inpatient until 37 weeks then induced
Outcomes Maternal morbidity, perinatal mortality, neurodevelopmental assessment at age 2
Shennan 2013 
Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
30
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Starting date April 2014. Anticipated to take approximately 3 years to recruit 900 women
Contact information Professor Andrew Shennan (andrew.shennan@kcl.ac.uk)
Notes ISRCTN01879376
Shennan 2013  (Continued)
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Planned early delivery versus expectant management (all women)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Composite maternal mor-
tality and morbidity
2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.57, 0.83]
2 Composite infant mortality
and morbidity
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Maternal mortality 2 1457 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Eclampsia 2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.14]
5 Pulmonary oedema 2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.17]
6 Severe renal impairment 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.14, 0.92]
7 HELLP syndrome 3 1628 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.17, 0.93]
8 Thromboembolic disease 2 1459 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.22, 12.58]
9 Abruptio placentae 3 1535 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.17, 2.34]
10 Postpartum haemorrhage 1 741 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.57, 1.35]
11 Severe hypertension 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
12 Caesarean section 4 1728 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.78, 1.07]
13 Assisted delivery (ven-
touse/forceps)
2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.70, 1.24]
14 Maternal morbidity of cae-
sarean section
1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.17, 3.35]
14.1 Endometritis 1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.17, 3.35]
15 Maternal morbidity relat-
ed to induction of labour
1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.1 Uterine rupture 1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
31
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
16 Admission to a high care
or intensive care unit
1 708 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.16, 1.07]
17 Fetal death 1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Neonatal death 3 1535 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.14]
19 Grade III or IV intraventric-
ular or intracerebral haemor-
rhage
1 674 Risk Ratio (M-H, Fixed, 95% CI) 6.92 [0.36, 133.41]
20 Nectrotising enterocolitis 2 1338 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.14, 6.89]
21 Respiratory distress syn-
drome
3 1511 Risk Ratio (M-H, Fixed, 95% CI) 2.24 [1.20, 4.18]
22 Small-for-gestational age 3 1001 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.89, 2.79]
23 Neonatal seizures 1 699 Risk Ratio (M-H, Fixed, 95% CI) 3.97 [0.45, 35.30]
24 Apgar score less than sev-
en at five minutes
2 1454 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.60, 2.05]
25 Cord blood pH less than
7.1 or as defined by trial au-
thors
2 1145 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.31, 1.09]
26 Surfactant use 1 639 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
27 Neonatal intensive care
unit or high care unit admis-
sion
4 1585 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [1.13, 2.40]
28 Early neonatal sepsis 2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
29 Duration of hospital stay
after delivery for mother
(days)
2 925 Mean Difference (IV, Fixed, 95% CI) -0.16 [-0.46, 0.15]
30 Duration of hospital stay
after delivery for baby (days)
1 756 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.57, 0.17]
 
 
Analysis 1.1.   Comparison 1 Planned early delivery versus expectant management
(all women), Outcome 1 Composite maternal mortality and morbidity.
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 4/352 11/351 6.24% 0.36[0.12,1.13]
Koopmans 2009 117/377 166/379 93.76% 0.71[0.59,0.86]
   
Favours delivery 1000.01 100.1 1 Favours expectant
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Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total (95% CI) 729 730 100% 0.69[0.57,0.83]
Total events: 121 (Delivery), 177 (Expectant)  
Heterogeneity: Tau2=0; Chi2=1.32, df=1(P=0.25); I2=24.31%  
Test for overall effect: Z=3.94(P<0.0001)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.2.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 2 Composite infant mortality and morbidity.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Broekhuijsen 2015 20/352 6/351 0% 3.32[1.35,8.18]
Koopmans 2009 24/377 32/379 0% 0.75[0.45,1.26]
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.3.   Comparison 1 Planned early delivery versus
expectant management (all women), Outcome 3 Maternal mortality.
Study or subgroup Delivery Expectant
Management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 0/352 0/351   Not estimable
Koopmans 2009 0/377 0/377   Not estimable
   
Total (95% CI) 729 728 Not estimable
Total events: 0 (Delivery), 0 (Expectant Management)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.4.   Comparison 1 Planned early delivery versus
expectant management (all women), Outcome 4 Eclampsia.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 0/352 2/351 100% 0.2[0.01,4.14]
Koopmans 2009 0/377 0/379   Not estimable
   
Total (95% CI) 729 730 100% 0.2[0.01,4.14]
Total events: 0 (Delivery), 2 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours delivery 1000.01 100.1 1 Favours expectant
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Analysis 1.5.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 5 Pulmonary oedema.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 0/352 0/351   Not estimable
Koopmans 2009 0/377 2/379 100% 0.2[0.01,4.17]
   
Total (95% CI) 729 730 100% 0.2[0.01,4.17]
Total events: 0 (Delivery), 2 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours delivery 2000.005 100.1 1 Favours expectant
 
 
Analysis 1.6.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 6 Severe renal impairment.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Majeed 2014 5/50 14/50 100% 0.36[0.14,0.92]
   
Total (95% CI) 50 50 100% 0.36[0.14,0.92]
Total events: 5 (Delivery), 14 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.14(P=0.03)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.7.   Comparison 1 Planned early delivery versus
expectant management (all women), Outcome 7 HELLP syndrome.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 3/352 6/351 32.22% 0.5[0.13,1.98]
Koopmans 2009 4/377 11/379 58.84% 0.37[0.12,1.14]
Owens 2014 0/94 1/75 8.94% 0.27[0.01,6.45]
   
Total (95% CI) 823 805 100% 0.4[0.17,0.93]
Total events: 7 (Delivery), 18 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=0.18, df=2(P=0.91); I2=0%  
Test for overall effect: Z=2.14(P=0.03)  
Favours delivery 1000.01 100.1 1 Favours expectant
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Analysis 1.8.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 8 Thromboembolic disease.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 1/352 1/351 66.76% 1[0.06,15.88]
Koopmans 2009 1/377 0/379 33.24% 3.02[0.12,73.8]
   
Total (95% CI) 729 730 100% 1.67[0.22,12.58]
Total events: 2 (Delivery), 1 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%  
Test for overall effect: Z=0.5(P=0.62)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.9.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 9 Abruptio placentae.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 0/352 2/351 45.49% 0.2[0.01,4.14]
Hamed 2014 3/38 3/38 54.51% 1[0.22,4.65]
Koopmans 2009 0/377 0/379   Not estimable
   
Total (95% CI) 767 768 100% 0.64[0.17,2.34]
Total events: 3 (Delivery), 5 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=0.9, df=1(P=0.34); I2=0%  
Test for overall effect: Z=0.68(P=0.5)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.10.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 10 Postpartum haemorrhage.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Koopmans 2009 35/370 40/371 100% 0.88[0.57,1.35]
   
Total (95% CI) 370 371 100% 0.88[0.57,1.35]
Total events: 35 (Delivery), 40 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.6(P=0.55)  
Favours delivery 1000.01 100.1 1 Favours expectant
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Analysis 1.11.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 11 Severe hypertension.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Hamed 2014 5/38 3/38 0% 1.67[0.43,6.49]
Koopmans 2009 62/373 103/377 0% 0.61[0.46,0.81]
Owens 2014 3/94 20/75 0% 0.12[0.04,0.39]
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.12.   Comparison 1 Planned early delivery versus
expectant management (all women), Outcome 12 Caesarean section.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 107/352 114/351 49.4% 0.94[0.75,1.16]
Koopmans 2009 54/377 72/379 31.07% 0.75[0.55,1.04]
Majeed 2014 12/50 14/50 6.06% 0.86[0.44,1.66]
Owens 2014 42/94 28/75 13.48% 1.2[0.83,1.73]
   
Total (95% CI) 873 855 100% 0.91[0.78,1.07]
Total events: 215 (Delivery), 228 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=3.51, df=3(P=0.32); I2=14.57%  
Test for overall effect: Z=1.17(P=0.24)  
Favours delivery 50.2 20.5 1 Favours expectant
 
 
Analysis 1.13.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 13 Assisted delivery (ventouse/forceps).
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 32/352 34/351 38.73% 0.94[0.59,1.49]
Koopmans 2009 50/377 54/379 61.27% 0.93[0.65,1.33]
   
Total (95% CI) 729 730 100% 0.93[0.7,1.24]
Total events: 82 (Delivery), 88 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
Favours delivery 1000.01 100.1 1 Favours expectant
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Analysis 1.14.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 14 Maternal morbidity of caesarean section.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.14.1 Endometritis  
Koopmans 2009 3/377 4/379 100% 0.75[0.17,3.35]
Subtotal (95% CI) 377 379 100% 0.75[0.17,3.35]
Total events: 3 (Delivery), 4 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.37(P=0.71)  
   
Total (95% CI) 377 379 100% 0.75[0.17,3.35]
Total events: 3 (Delivery), 4 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.37(P=0.71)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.15.   Comparison 1 Planned early delivery versus expectant management
(all women), Outcome 15 Maternal morbidity related to induction of labour.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.15.1 Uterine rupture  
Koopmans 2009 0/377 0/379   Not estimable
Subtotal (95% CI) 377 379 Not estimable
Total events: 0 (Delivery), 0 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 377 379 Not estimable
Total events: 0 (Delivery), 0 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.16.   Comparison 1 Planned early delivery versus expectant management
(all women), Outcome 16 Admission to a high care or intensive care unit.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Koopmans 2009 6/360 14/348 100% 0.41[0.16,1.07]
   
Total (95% CI) 360 348 100% 0.41[0.16,1.07]
Total events: 6 (Delivery), 14 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.83(P=0.07)  
Favours delivery 1000.01 100.1 1 Favours expectant
Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
37
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
Analysis 1.17.   Comparison 1 Planned early delivery versus
expectant management (all women), Outcome 17 Fetal death.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Koopmans 2009 0/377 0/379   Not estimable
   
Total (95% CI) 377 379 Not estimable
Total events: 0 (Delivery), 0 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.18.   Comparison 1 Planned early delivery versus
expectant management (all women), Outcome 18 Neonatal death.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 0/352 0/351   Not estimable
Hamed 2014 2/38 1/38 100% 2[0.19,21.14]
Koopmans 2009 0/377 0/379   Not estimable
   
Total (95% CI) 767 768 100% 2[0.19,21.14]
Total events: 2 (Delivery), 1 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.58(P=0.56)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.19.   Comparison 1 Planned early delivery versus expectant management
(all women), Outcome 19 Grade III or IV intraventricular or intracerebral haemorrhage.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 3/339 0/335 100% 6.92[0.36,133.41]
   
Total (95% CI) 339 335 100% 6.92[0.36,133.41]
Total events: 3 (Delivery), 0 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.28(P=0.2)  
Favours delivery 2000.005 100.1 1 Favours expectant
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Analysis 1.20.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 20 Nectrotising enterocolitis.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 1/351 0/348 24.76% 2.97[0.12,72.76]
Koopmans 2009 0/325 1/314 75.24% 0.32[0.01,7.88]
   
Total (95% CI) 676 662 100% 0.98[0.14,6.89]
Total events: 1 (Delivery), 1 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=0.93, df=1(P=0.34); I2=0%  
Test for overall effect: Z=0.02(P=0.98)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.21.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 21 Respiratory distress syndrome.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 20/352 6/351 43.86% 3.32[1.35,8.18]
Koopmans 2009 1/325 1/314 7.42% 0.97[0.06,15.38]
Owens 2014 11/94 6/75 48.72% 1.46[0.57,3.77]
   
Total (95% CI) 771 740 100% 2.24[1.2,4.18]
Total events: 32 (Delivery), 13 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=1.87, df=2(P=0.39); I2=0%  
Test for overall effect: Z=2.54(P=0.01)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.22.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 22 Small-for-gestational age.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hamed 2014 6/38 4/38 23.9% 1.5[0.46,4.89]
Koopmans 2009 3/377 0/379 2.98% 7.04[0.36,135.77]
Owens 2014 19/94 11/75 73.12% 1.38[0.7,2.71]
   
Total (95% CI) 509 492 100% 1.58[0.89,2.79]
Total events: 28 (Delivery), 15 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=1.14, df=2(P=0.57); I2=0%  
Test for overall effect: Z=1.56(P=0.12)  
Favours delivery 1000.01 100.1 1 Favours expectant
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Analysis 1.23.   Comparison 1 Planned early delivery versus
expectant management (all women), Outcome 23 Neonatal seizures.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 4/351 1/348 100% 3.97[0.45,35.3]
   
Total (95% CI) 351 348 100% 3.97[0.45,35.3]
Total events: 4 (Delivery), 1 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.24(P=0.22)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.24.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 24 Apgar score less than seven at five minutes.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 14/351 10/350 52.83% 1.4[0.63,3.1]
Koopmans 2009 7/374 9/379 47.17% 0.79[0.3,2.09]
   
Total (95% CI) 725 729 100% 1.11[0.6,2.05]
Total events: 21 (Delivery), 19 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=0.79, df=1(P=0.37); I2=0%  
Test for overall effect: Z=0.33(P=0.74)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.25.   Comparison 1 Planned early delivery versus expectant management
(all women), Outcome 25 Cord blood pH less than 7.1 or as defined by trial authors.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 6/270 6/263 23.94% 0.97[0.32,2.98]
Koopmans 2009 9/311 19/301 76.06% 0.46[0.21,1]
   
Total (95% CI) 581 564 100% 0.58[0.31,1.09]
Total events: 15 (Delivery), 25 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=1.18, df=1(P=0.28); I2=14.98%  
Test for overall effect: Z=1.69(P=0.09)  
Favours delivery 1000.01 100.1 1 Favours expectant
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Analysis 1.26.   Comparison 1 Planned early delivery versus
expectant management (all women), Outcome 26 Surfactant use.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Koopmans 2009 0/325 0/314   Not estimable
   
Total (95% CI) 325 314 Not estimable
Total events: 0 (Delivery), 0 (Expectant management)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.27.   Comparison 1 Planned early delivery versus expectant management
(all women), Outcome 27 Neonatal intensive care unit or high care unit admission.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 26/352 13/350 32.81% 1.99[1.04,3.81]
Hamed 2014 12/38 3/38 7.55% 4[1.23,13.05]
Koopmans 2009 10/324 8/314 20.45% 1.21[0.48,3.03]
Owens 2014 20/94 14/75 39.19% 1.14[0.62,2.1]
   
Total (95% CI) 808 777 100% 1.65[1.13,2.4]
Total events: 68 (Delivery), 38 (Expectant management)  
Heterogeneity: Tau2=0; Chi2=4.31, df=3(P=0.23); I2=30.41%  
Test for overall effect: Z=2.62(P=0.01)  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.28.   Comparison 1 Planned early delivery versus expectant
management (all women), Outcome 28 Early neonatal sepsis.
Study or subgroup Delivery Expectant
management
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Broekhuijsen 2015 36/351 22/348 0% 1.62[0.97,2.7]
Koopmans 2009 0/377 1/379 0% 0.34[0.01,8.2]
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.29.   Comparison 1 Planned early delivery versus expectant management
(all women), Outcome 29 Duration of hospital stay a8er delivery for mother (days).
Study or subgroup Delivery Expectant Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Koopmans 2009 377 1.6 (1.8) 379 1.9 (3.9) 50.31% -0.3[-0.73,0.13]
Favours delivery 42-4 -2 0 Favours expectant
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Study or subgroup Delivery Expectant Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Owens 2014 94 3.1 (1.3) 75 3.1 (1.6) 49.69% -0.01[-0.45,0.43]
   
Total *** 471   454   100% -0.16[-0.46,0.15]
Heterogeneity: Tau2=0; Chi2=0.86, df=1(P=0.35); I2=0%  
Test for overall effect: Z=1(P=0.32)  
Favours delivery 42-4 -2 0 Favours expectant
 
 
Analysis 1.30.   Comparison 1 Planned early delivery versus expectant management
(all women), Outcome 30 Duration of hospital stay a8er delivery for baby (days).
Study or subgroup Delivery Expectant Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Koopmans 2009 377 2.5 (2.4) 379 2.7 (2.8) 100% -0.2[-0.57,0.17]
   
Total *** 377   379   100% -0.2[-0.57,0.17]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
Favours delivery 10050-100 -50 0 Favours expectant
 
 
Comparison 2.   Planned early delivery versus expectant management (by gestational age)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Composite maternal mortality and
morbidity
2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.57, 0.83]
1.1 34 + 0 to 36 + 6 weeks GA at randomi-
sation
2 778 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.48, 1.24]
1.2 37 + 0 to 38 + 6 weeks GA at randomi-
sation
1 380 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.53, 0.90]
1.3 39 + 0 to 41 + 0 weeks GA at randomi-
sation
1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.47, 0.88]
2 Respiratory distress syndrome 2 1459 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.16, 5.55]
2.1 34 + 0 to 36 + 6 weeks GA at randomi-
sation
2 778 Risk Ratio (M-H, Fixed, 95% CI) 3.32 [1.35, 8.18]
2.2 37 + 0 to 38 + 6 weeks GA at randomi-
sation
1 380 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.72]
2.3 39 + 0 to 41 + 0 weeks GA at randomi-
sation
1 301 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.07, 17.74]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Composite infant mortality and mor-
bidity
1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.46, 1.28]
3.1 36 + 0 to 36 + 6 weeks GA at randomi-
sation
1 75 Risk Ratio (M-H, Fixed, 95% CI) 2.63 [0.29, 24.10]
3.2 37 + 0 to 38 + 6 weeks GA at randomi-
sation
1 380 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.31, 1.49]
3.3 39 + 0 to 41 + 0 weeks GA at randomi-
sation
1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.35, 1.49]
 
 
Analysis 2.1.   Comparison 2 Planned early delivery versus expectant management
(by gestational age), Outcome 1 Composite maternal mortality and morbidity.
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.1.1 34 + 0 to 36 + 6 weeks GA at randomisation  
Broekhuijsen 2015 4/352 11/351 6.25% 0.36[0.12,1.13]
Koopmans 2009 18/40 15/35 9.08% 1.05[0.63,1.75]
Subtotal (95% CI) 392 386 15.33% 0.77[0.48,1.24]
Total events: 22 (Delivery), 26 (Expectant)  
Heterogeneity: Tau2=0; Chi2=3.09, df=1(P=0.08); I2=67.69%  
Test for overall effect: Z=1.08(P=0.28)  
   
2.1.2 37 + 0 to 38 + 6 weeks GA at randomisation  
Koopmans 2009 59/195 81/185 47.18% 0.69[0.53,0.9]
Subtotal (95% CI) 195 185 47.18% 0.69[0.53,0.9]
Total events: 59 (Delivery), 81 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.7(P=0.01)  
   
2.1.3 39 + 0 to 41 + 0 weeks GA at randomisation  
Koopmans 2009 40/142 70/159 37.49% 0.64[0.47,0.88]
Subtotal (95% CI) 142 159 37.49% 0.64[0.47,0.88]
Total events: 40 (Delivery), 70 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.77(P=0.01)  
   
Total (95% CI) 729 730 100% 0.68[0.57,0.83]
Total events: 121 (Delivery), 177 (Expectant)  
Heterogeneity: Tau2=0; Chi2=4.06, df=3(P=0.26); I2=26.02%  
Test for overall effect: Z=3.96(P<0.0001)  
Test for subgroup differences: Chi2=0.41, df=1 (P=0.81), I2=0%  
Favours delivery 1000.01 100.1 1 Favours expectant
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Analysis 2.2.   Comparison 2 Planned early delivery versus expectant
management (by gestational age), Outcome 2 Respiratory distress syndrome.
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.2.1 34 + 0 to 36 + 6 weeks GA at randomisation  
Broekhuijsen 2015 20/352 6/351 70.76% 3.32[1.35,8.18]
Koopmans 2009 0/40 0/35   Not estimable
Subtotal (95% CI) 392 386 70.76% 3.32[1.35,8.18]
Total events: 20 (Delivery), 6 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.62(P=0.01)  
   
2.2.2 37 + 0 to 38 + 6 weeks GA at randomisation  
Koopmans 2009 0/195 1/185 18.13% 0.32[0.01,7.72]
Subtotal (95% CI) 195 185 18.13% 0.32[0.01,7.72]
Total events: 0 (Delivery), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
2.2.3 39 + 0 to 41 + 0 weeks GA at randomisation  
Koopmans 2009 1/142 1/159 11.11% 1.12[0.07,17.74]
Subtotal (95% CI) 142 159 11.11% 1.12[0.07,17.74]
Total events: 1 (Delivery), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.08(P=0.94)  
   
Total (95% CI) 729 730 100% 2.53[1.16,5.55]
Total events: 21 (Delivery), 8 (Expectant)  
Heterogeneity: Tau2=0; Chi2=2.31, df=2(P=0.31); I2=13.6%  
Test for overall effect: Z=2.32(P=0.02)  
Test for subgroup differences: Chi2=2.31, df=1 (P=0.31), I2=13.54%  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 2.3.   Comparison 2 Planned early delivery versus expectant management
(by gestational age), Outcome 3 Composite infant mortality and morbidity.
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.3.1 36 + 0 to 36 + 6 weeks GA at randomisation  
Koopmans 2009 3/40 1/35 3.39% 2.63[0.29,24.1]
Subtotal (95% CI) 40 35 3.39% 2.63[0.29,24.1]
Total events: 3 (Delivery), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.39)  
   
2.3.2 37 + 0 to 38 + 6 weeks GA at randomisation  
Koopmans 2009 10/195 14/185 45.65% 0.68[0.31,1.49]
Subtotal (95% CI) 195 185 45.65% 0.68[0.31,1.49]
Total events: 10 (Delivery), 14 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.97(P=0.33)  
Favours delivery 1000.01 100.1 1 Favours expectant
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Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
2.3.3 39 + 0 to 41 + 0 weeks GA at randomisation  
Koopmans 2009 11/142 17/159 50.96% 0.72[0.35,1.49]
Subtotal (95% CI) 142 159 50.96% 0.72[0.35,1.49]
Total events: 11 (Delivery), 17 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.87(P=0.38)  
   
Total (95% CI) 377 379 100% 0.77[0.46,1.28]
Total events: 24 (Delivery), 32 (Expectant)  
Heterogeneity: Tau2=0; Chi2=1.3, df=2(P=0.52); I2=0%  
Test for overall effect: Z=1.01(P=0.31)  
Test for subgroup differences: Chi2=1.3, df=1 (P=0.52), I2=0%  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Comparison 3.   Planned early delivery versus expectant management (by each gestational week)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Composite maternal mortality and
morbidity
2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.57, 0.83]
1.1 34 + 0 to 34 + 6 weeks GA at ran-
domisation
1 154 Risk Ratio (M-H, Fixed, 95% CI) 4.75 [0.23, 97.34]
1.2 35 + 0 to 35 + 6 weeks GA at ran-
domisation
1 236 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.10]
1.3 36 + 0 to 36 + 6 weeks GA at ran-
domisation
2 388 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.59, 1.62]
1.4 37 + 0 to 37 + 6 weeks GA at ran-
domisation
1 188 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.52, 1.08]
1.5 38 + 0 to 38 + 6 weeks GA at ran-
domisation
1 192 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.43, 0.94]
1.6 39 + 0 to 39 + 6 weeks GA at ran-
domisation
1 186 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.53, 1.14]
1.7 40 + 0 to 41 + 0 weeks GA at ran-
domisation
1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.26, 0.79]
2 Respiratory distress syndrome 1 703 Risk Ratio (M-H, Fixed, 95% CI) 3.32 [1.38, 8.01]
2.1 34 + 0 to 34 + 6 weeks GA at ran-
domisation
1 154 Risk Ratio (M-H, Fixed, 95% CI) 2.37 [0.78, 7.24]
2.2 35 + 0 to 35 + 6 weeks GA at ran-
domisation
1 236 Risk Ratio (M-H, Fixed, 95% CI) 7.62 [0.93, 62.27]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.3 36 + 0 to 36 + 6 weeks GA at ran-
domisation
1 313 Risk Ratio (M-H, Fixed, 95% CI) 3.41 [0.39, 30.15]
3 Composite infant mortality and mor-
bidity
1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.46, 1.29]
3.1 36 + 0 to 36 + 6 weeks GA at ran-
domisation
1 75 Risk Ratio (M-H, Fixed, 95% CI) 2.63 [0.29, 24.10]
3.2 37 + 0 to 37 + 6 weeks GA at ran-
domisation
1 188 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.17, 1.35]
3.3 38 + 0 to 38 + 6 weeks GA at ran-
domisation
1 192 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.33, 4.24]
3.4 39 + 0 to 39 + 6 weeks GA at ran-
domisation
1 186 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.32, 1.95]
3.5 40 + 0 to 41 + 0 weeks GA at ran-
domisation
1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.19, 2.12]
 
 
Analysis 3.1.   Comparison 3 Planned early delivery versus expectant management
(by each gestational week), Outcome 1 Composite maternal mortality and morbidity.
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.1.1 34 + 0 to 34 + 6 weeks GA at randomisation  
Broekhuijsen 2015 2/79 0/75 0.29% 4.75[0.23,97.34]
Subtotal (95% CI) 79 75 0.29% 4.75[0.23,97.34]
Total events: 2 (Delivery), 0 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
   
3.1.2 35 + 0 to 35 + 6 weeks GA at randomisation  
Broekhuijsen 2015 1/104 9/132 4.51% 0.14[0.02,1.1]
Subtotal (95% CI) 104 132 4.51% 0.14[0.02,1.1]
Total events: 1 (Delivery), 9 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.87(P=0.06)  
   
3.1.3 36 + 0 to 36 + 6 weeks GA at randomisation  
Broekhuijsen 2015 1/169 2/144 1.23% 0.43[0.04,4.65]
Koopmans 2009 18/40 15/35 9.1% 1.05[0.63,1.75]
Subtotal (95% CI) 209 179 10.33% 0.98[0.59,1.62]
Total events: 19 (Delivery), 17 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.54, df=1(P=0.46); I2=0%  
Test for overall effect: Z=0.1(P=0.92)  
   
3.1.4 37 + 0 to 37 + 6 weeks GA at randomisation  
Favours delivery 1000.01 100.1 1 Favours expectant
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Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Koopmans 2009 32/96 41/92 23.82% 0.75[0.52,1.08]
Subtotal (95% CI) 96 92 23.82% 0.75[0.52,1.08]
Total events: 32 (Delivery), 41 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.57(P=0.12)  
   
3.1.5 38 + 0 to 38 + 6 weeks GA at randomisation  
Koopmans 2009 27/99 40/93 23.46% 0.63[0.43,0.94]
Subtotal (95% CI) 99 93 23.46% 0.63[0.43,0.94]
Total events: 27 (Delivery), 40 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.24(P=0.02)  
   
3.1.6 39 + 0 to 39 + 6 weeks GA at randomisation  
Koopmans 2009 27/83 43/103 21.83% 0.78[0.53,1.14]
Subtotal (95% CI) 83 103 21.83% 0.78[0.53,1.14]
Total events: 27 (Delivery), 43 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.27(P=0.2)  
   
3.1.7 40 + 0 to 41 + 0 weeks GA at randomisation  
Koopmans 2009 13/59 27/56 15.76% 0.46[0.26,0.79]
Subtotal (95% CI) 59 56 15.76% 0.46[0.26,0.79]
Total events: 13 (Delivery), 27 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.78(P=0.01)  
   
Total (95% CI) 729 730 100% 0.69[0.57,0.83]
Total events: 121 (Delivery), 177 (Expectant)  
Heterogeneity: Tau2=0; Chi2=9.49, df=7(P=0.22); I2=26.21%  
Test for overall effect: Z=3.87(P=0)  
Test for subgroup differences: Chi2=8.5, df=1 (P=0.2), I2=29.37%  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 3.2.   Comparison 3 Planned early delivery versus expectant management
(by each gestational week), Outcome 2 Respiratory distress syndrome.
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.2.1 34 + 0 to 34 + 6 weeks GA at randomisation  
Broekhuijsen 2015 10/79 4/75 67.66% 2.37[0.78,7.24]
Subtotal (95% CI) 79 75 67.66% 2.37[0.78,7.24]
Total events: 10 (Delivery), 4 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.52(P=0.13)  
   
3.2.2 35 + 0 to 35 + 6 weeks GA at randomisation  
Broekhuijsen 2015 6/104 1/132 14.53% 7.62[0.93,62.27]
Subtotal (95% CI) 104 132 14.53% 7.62[0.93,62.27]
Favours delivery 500.02 100.1 1 Favours expectant
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Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 6 (Delivery), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.89(P=0.06)  
   
3.2.3 36 + 0 to 36 + 6 weeks GA at randomisation  
Broekhuijsen 2015 4/169 1/144 17.8% 3.41[0.39,30.15]
Subtotal (95% CI) 169 144 17.8% 3.41[0.39,30.15]
Total events: 4 (Delivery), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
   
Total (95% CI) 352 351 100% 3.32[1.38,8.01]
Total events: 20 (Delivery), 6 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.95, df=2(P=0.62); I2=0%  
Test for overall effect: Z=2.67(P=0.01)  
Test for subgroup differences: Chi2=0.93, df=1 (P=0.63), I2=0%  
Favours delivery 500.02 100.1 1 Favours expectant
 
 
Analysis 3.3.   Comparison 3 Planned early delivery versus expectant management
(by each gestational week), Outcome 3 Composite infant mortality and morbidity.
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.3.1 36 + 0 to 36 + 6 weeks GA at randomisation  
Koopmans 2009 3/40 1/35 3.4% 2.63[0.29,24.1]
Subtotal (95% CI) 40 35 3.4% 2.63[0.29,24.1]
Total events: 3 (Delivery), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.39)  
   
3.3.2 37 + 0 to 37 + 6 weeks GA at randomisation  
Koopmans 2009 5/96 10/92 32.55% 0.48[0.17,1.35]
Subtotal (95% CI) 96 92 32.55% 0.48[0.17,1.35]
Total events: 5 (Delivery), 10 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.39(P=0.16)  
   
3.3.3 38 + 0 to 38 + 6 weeks GA at randomisation  
Koopmans 2009 5/99 4/93 13.15% 1.17[0.33,4.24]
Subtotal (95% CI) 99 93 13.15% 1.17[0.33,4.24]
Total events: 5 (Delivery), 4 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.81)  
   
3.3.4 39 + 0 to 39 + 6 weeks GA at randomisation  
Koopmans 2009 7/83 11/103 31.29% 0.79[0.32,1.95]
Subtotal (95% CI) 83 103 31.29% 0.79[0.32,1.95]
Total events: 7 (Delivery), 11 (Expectant)  
Heterogeneity: Not applicable  
Favours delivery 1000.01 100.1 1 Favours expectant
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Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Test for overall effect: Z=0.51(P=0.61)  
   
3.3.5 40 + 0 to 41 + 0 weeks GA at randomisation  
Koopmans 2009 4/59 6/56 19.62% 0.63[0.19,2.12]
Subtotal (95% CI) 59 56 19.62% 0.63[0.19,2.12]
Total events: 4 (Delivery), 6 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.74(P=0.46)  
   
Total (95% CI) 377 379 100% 0.77[0.46,1.29]
Total events: 24 (Delivery), 32 (Expectant)  
Heterogeneity: Tau2=0; Chi2=2.5, df=4(P=0.64); I2=0%  
Test for overall effect: Z=1(P=0.32)  
Test for subgroup differences: Chi2=2.5, df=1 (P=0.64), I2=0%  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Comparison 4.   Planned early delivery versus expectant management (by condition)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Composite maternal mortality and mor-
bidity
2 1445 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.58, 0.85]
1.1 Gestational hypertension 2 678 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.61, 1.00]
1.2 Mild pre-eclampsia 2 570 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.45, 0.81]
1.3 Chronic hypertension 1 197 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.10, 2.86]
2 Respiratory distress syndrome 1 703 Risk Ratio (M-H, Fixed, 95% CI) 3.36 [1.36, 8.31]
2.1 Gestational hypertension 1 182 Risk Ratio (M-H, Fixed, 95% CI) 3.91 [0.45, 34.34]
2.2 Mild pre-eclampsia 1 324 Risk Ratio (M-H, Fixed, 95% CI) 4.82 [1.07, 21.65]
2.3 Chronic hypertension 1 197 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [0.55, 8.35]
 
 
Analysis 4.1.   Comparison 4 Planned early delivery versus expectant management
(by condition), Outcome 1 Composite maternal mortality and morbidity.
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.1.1 Gestational hypertension  
Broekhuijsen 2015 0/92 3/90 2.05% 0.14[0.01,2.67]
Koopmans 2009 75/244 96/252 54.62% 0.81[0.63,1.03]
Subtotal (95% CI) 336 342 56.67% 0.78[0.61,1]
Favours delivery 1000.01 100.1 1 Favours expectant
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Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 75 (Delivery), 99 (Expectant)  
Heterogeneity: Tau2=0; Chi2=1.37, df=1(P=0.24); I2=26.98%  
Test for overall effect: Z=1.96(P=0.05)  
   
4.1.2 Mild pre-eclampsia  
Broekhuijsen 2015 2/165 4/159 2.36% 0.48[0.09,2.59]
Koopmans 2009 41/123 67/123 38.75% 0.61[0.45,0.82]
Subtotal (95% CI) 288 282 41.1% 0.6[0.45,0.81]
Total events: 43 (Delivery), 71 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%  
Test for overall effect: Z=3.34(P=0)  
   
4.1.3 Chronic hypertension  
Broekhuijsen 2015 2/95 4/102 2.23% 0.54[0.1,2.86]
Subtotal (95% CI) 95 102 2.23% 0.54[0.1,2.86]
Total events: 2 (Delivery), 4 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
   
Total (95% CI) 719 726 100% 0.7[0.58,0.85]
Total events: 120 (Delivery), 174 (Expectant)  
Heterogeneity: Tau2=0; Chi2=3.49, df=4(P=0.48); I2=0%  
Test for overall effect: Z=3.68(P=0)  
Test for subgroup differences: Chi2=1.85, df=1 (P=0.4), I2=0%  
Favours delivery 1000.01 100.1 1 Favours expectant
 
 
Analysis 4.2.   Comparison 4 Planned early delivery versus expectant
management (by condition), Outcome 2 Respiratory distress syndrome.
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.2.1 Gestational hypertension  
Broekhuijsen 2015 4/92 1/90 17.02% 3.91[0.45,34.34]
Subtotal (95% CI) 92 90 17.02% 3.91[0.45,34.34]
Total events: 4 (Delivery), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.23(P=0.22)  
   
4.2.2 Mild pre-eclampsia  
Broekhuijsen 2015 10/165 2/159 34.29% 4.82[1.07,21.65]
Subtotal (95% CI) 165 159 34.29% 4.82[1.07,21.65]
Total events: 10 (Delivery), 2 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.05(P=0.04)  
   
4.2.3 Chronic hypertension  
Broekhuijsen 2015 6/95 3/102 48.7% 2.15[0.55,8.35]
Subtotal (95% CI) 95 102 48.7% 2.15[0.55,8.35]
Total events: 6 (Delivery), 3 (Expectant)  
Favours delivery 1000.01 100.1 1 Favours expectant
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Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
   
Total (95% CI) 352 351 100% 3.36[1.36,8.31]
Total events: 20 (Delivery), 6 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.66, df=2(P=0.72); I2=0%  
Test for overall effect: Z=2.63(P=0.01)  
Test for subgroup differences: Chi2=0.65, df=1 (P=0.72), I2=0%  
Favours delivery 1000.01 100.1 1 Favours expectant
 
H I S T O R Y
Protocol first published: Issue 8, 2011
Review first published: Issue 1, 2017
 
Date Event Description
14 January 2014 Amended For clarification, the gestational age in the title has been
changed from "at or near term" to "from 34 weeks to term".
12 December 2012 Amended This scope of this protocol has been expanded to incorporate all
hypertensive disorders of pregnancy and not just pre-eclampsia.
The methods section (Assessment of reporting biases/Subgroup
analysis and investigation of heterogeneity) has been updated to
incorporate the Cochrane Pregnancy and Childbirth Groups' up-
dated standard methods text.
A new co-author (C M Koopmans) has joined the review team.
 
C O N T R I B U T I O N S   O F   A U T H O R S
CC helped develop the protocol, extracted the data, checked data entry, helped write the review and is the guarantor for the review.
NN prepared the original protocol assisted and with the preparation of this review.
CK assisted with the preparation the protocol and review.
HW extracted the data, entered the data and helped write this review.
D E C L A R A T I O N S   O F   I N T E R E S T
CK is an author of an included study in this review (Koopmans 2009). All decisions relating to this study (assessment for inclusion/exclusion,
risk of bias and data extraction) were carried out by the other members of the review team who are not directly involved in the study.
HW is paid to work on Cochrane reviews by a grant to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are
those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
CC: none known.
NN: none known.
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S O U R C E S   O F   S U P P O R T
Internal sources• (NN) Walter Sisulu Univeristy, East London Hospital Complex, South Africa.
NN was employed by East London Hospital Complex attached to Walter Sisulu University.• (HW) Cochrane Pregnancy and Childbirth Group, Department of Women's and Children's Health, The University of Liverpool, Liverpool,
UK.• (CC) Stellenbosch University, Cape Town, South Africa.
Cathy Cluver is registered for PhD at Stellenbosch University
External sources• NIHR Cochrane Programme Grant Project: 13/89/05 – Pregnancy and childbirth systematic reviews to support clinical guidelines, UK.• (CC) Discovery Foundation, South Africa.
CC has been awarded the Discovery Accademic Fellowship• (CC) South African Medical Association, South Africa.
CC has been awarded the SAMA Fellowship
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We have edited the review title from 'Delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term' to
'Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term'.
Our Types of studies and Types of interventions sections have been edited to incorporate 'planned early delivery' as per the modified title.
The methods have been updated to reflect current standard methods text of Cochrane Pregnancy and Childbirth and we have updated
some sections of the background.
We have used the GRADEpro Guideline Development Tool to assess the quality of the evidence included in this review. We have also include
a Summary of findings for the main comparison.
Respiratory distress syndrome was analysed by subgroup, in addition to the prespecified composite maternal and infant outcomes, as the
composite infant outcomes is not yet available by gestational age for Broekhuijsen 2015.
Changes to outcomes
Changes to maternal outcomes
We have made a number of changes to our protocol outcomes for maternal outcomes.
Primary outcome
The nature of the maternal composite outcome has been further clarified at the review stage:
• Protocol = Composite maternal outcome including maternal mortality (death during pregnancy or up to 42 days after end of pregnancy)
and severe morbidity (eclampsia, stroke, renal or liver failure as defined below), haemolysis, elevated liver enzymes and low platelets
syndrome (HELLP), disseminated intravascular coagulation (DIC), pulmonary oedema, thromboembolic disease, cardiac arrest, abrup-
tion of the placenta or antepartum haemorrhage).• Review = ' Composite maternal outcome including maternal mortality (death during pregnancy or up to 42 days after delivery) and
severe morbidity (eclampsia, cerebral vascular event, pulmonary oedema as defined by trial authors, severe renal impairment defined
as a creatinine level greater than 125 μmol/l or a need for dialysis or urine output less than 0.5 mL/kg/hour for four hours unresponsive
to hydration with two intravenous boluses, or as defined by trial authors, liver haematoma or rupture, liver failure defined as the rapid
impairment of synthetic function and development of encephalopathy or as defined by trial authors, haemolysis elevated liver enzymes
and low platelets (HELLP) syndrome, disseminated intravascular coagulation (DIC), thromboembolic disease and abruptio placentae
defined as a retroplacental clot of more than 15% of the maternal surface or as defined by trial authors.
Secondary outcomes
Our secondary outcomes edited accordingly:
• 'Death as defined above' has been edited to 'Maternal mortality as described above'• 'Eclampsia (fitting)' has been edited to 'Eclampsia'
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• Stroke (brain damage) has been edited to 'Cerebrovascular event'• 'Pulmonary oedema (fluid in the lungs)' has been edited to 'Pulmonary oedema'• 'Kidney failure (defined as rise in serum creatine concentration by > 1 mg/dL over baseline) and/or urine output less than 0.5 mL/kg/hr
for two hours unresponsive to hydration with two intravenous boluses of 500 mL fluid), or as defined by trial authors' has been edited
to 'Severe renal impairment as defined above'• 'Liver failure (the rapid impairment of synthetic function and development of encephalopathy) or as defined by trial authors' has been
edited to 'Liver failure as defined above'• 'Abruption of the placenta or antepartum haemorrhage' has been split into two separate outcomes, 'Abruptio placentae' and 'Antepar-
tum haemorrhage'• 'Postpartum haemorrhage (blood loss 500 mL or more' has been edited to 'Postpartum haemorrhage (blood loss of more than 500 mL
within 24 hours of delivery'
The following secondary outcomes have been added at the review stage:
• 'Liver haematoma or rupture'• 'Admission to a high care or intensive care unit'
Changes to fetal/neonatal outcomes
We have made a number of changes to our protocol outcomes for fetal/neonatal outcomes:
Primary outcome
The nature of the perinatal composite outcome has been further clarified at the review stage:
• Protocol = Composite perinatal outcome (perinatal death (stillbirth or death in the first seven days of life), small-for-gestational age
(growth below the third centile or lowest centile reported), acute respiratory distress syndrome (ARDS), necrotising enterocolitis (NEC),
cerebral haemorrhage, Apgar score less than seven or very low (less than four) at five minutes, cord blood pH less than 7.1, neonatal
seizures, intraventricular haemorrhage)• Review = 'Composite perinatal outcome including fetal or neonatal death (within six weeks after the expected due date or as defined
by trial authors), grade III or IV intraventricular or intracerebral haemorrhage, necrotising enterocolitis (NEC), acute respiratory distress
syndrome (ARDS) or grade III/IV hyaline membrane disease, small-for-gestational age (growth below the 10th centile or as defined by
trial authors) and neonatal seizures.
Secondary outcomes
Our secondary outcomes edited accordingly:
• 'Stillbirth', 'perinatal death' and 'neonatal death' have been replaced with 'fetal death', neonatal death (as defined in the primary out-
come above).• 'Intraventricular haemorrhage' has been edited to 'Grade III or IV intraventricular or intracerebral haemorrhage'.• 'ARDS' has been edited to 'ARDS or grade III/IV hyaline membrane disease'• The outcome 'small-for-gestational age' was changed to 'small-for-gestational age as defined by trial authors', with definitions given
in the footnotes of the data• 'Apgar score at five minutes: low (less than seven), very low (less than four) or lowest reported' has been replaced with 'Apgar score
less than seven at five minutes'• 'Cord blood pH less than 7.1' has been edited to 'Cord blood pH less than 7.1 or as defined by the trial authors'• 'Endotracheal intubation or use of mechanical ventilation' has been edited to 'Intubation and mechanical ventilation or continuous
positive airway pressure support'
The following secondary outcomes have been added at the review stage:
• 'Early neonatal sepsis'• 'Surfactant use'• 'Neonatal intensive care unit use or high care unit admission'
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Cesarean Section  [statistics & numerical data];  *Hypertension;  *Labor, Induced  [statistics & numerical data];  *Pregnancy Complications,
Cardiovascular;   *Watchful Waiting;   Delivery, Obstetric;   Gestational Age;   Infant Mortality;   Length of Stay;   Maternal Mortality;   Pre-
Eclampsia;  Randomized Controlled Trials as Topic
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MeSH check words
Female; Humans; Infant; Infant, Newborn; Pregnancy
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